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1 
METHODS AND COMPOSITIONS FOR 
NAD(P)(H) OXIDASES 
2 
eration, however, from NAD(P)H to oxidized cofactors 
NAD+ or NADP+, no universally accepted system exists. 
There are some currently known NADH oxidases that are 
able to oxidize NADH to NAD+ with simultaneous reduc-CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application, filed Jan. 28, 2005, is a continuation of 
PCT/US2003/024067, filed Jul. 31, 2003, which claims the 
priority of U.S. Provisional Patent Application Ser. No. 
60/399,850, filed Jul. 31, 2002. 
5 tion of 0 2 to either H20 2 or H20 [30-34]. Four-electron 
reduction to benign H2 0 is preferred over two-electron 
reduction to H20 2 , which, even in small amounts, can 
deactivate either enzyme of the production-regeneration 
cycle. Addition of catalase as a possible remedy, to degrade 
FIELD OF THE INVENTION 
10 the H2 0 2 , increases complexity of the system to the point 
where three enzymes have to be coupled and adjusted as to 
their activity over time. 
The present invention relates to bacterial NAD(P)H oxi-
dases, their purification, nucleic acids coding for them and 
vehicles and constructs comprising the nucleic acids or 
expressed products of the nucleic acids, and products made 
from enzymatic reactions using the oxidases. 
For reductive reactions with dehydrogenases or for 
monooxygenases, NAD(P)H has to be regenerated from 
15 NAD(Pt. For this problem, the system formate dehydro-
genase (FDH)/formate is now used almost universally 
[35-37 
BACKGROUND OF THE INVENTION 20 
Enantiomerically pure compounds (EPCs ), especially 
amino and hydroxy acids as well as alcohols, amines, and 
lactones are increasingly useful in the pharmaceutical, food, 
25 
and crop protection industries as building blocks for novel 
compounds not accessible through fermentation [1-4] as 
well as for asymmetric synthesis templates.[5-6] One very 
advantageous route to a wide variety of EPCs is the use of 
dehydrogenases, to afford either reduction of keto com-
30 
pounds or oxidation of alcohol or amine groups. The rep-
ertoire of dehydrogenases useful for synthesis of EPCs 
encompasses alcohol dehydrogenases (ADHs) [7], D- and 
L-lactate dehydrogenases (LDHs) [8], D- or L-hydroxyiso-
caproate dehydrogenases (D- or L-HicDHs) [9, 1 OJ, or amino 
35 
acid dehydrogenases such as leucine dehydrogenase 
(LeuDH) [10], phenylalanine dehydrogenase (PheDH) 
[11-13] or glutamate dehydrogenase (GluDH).[14] 
Monooxygenases have been used to synthesize, regio- and 
enantioselectively, lactones from cyclic ketones useful in the 
40 
flavor and fragrance industries.[15] 
HCOOH+NAD+ ~NADH+H• +C02 (1) 
FDH functions as a universal regeneration enzyme in tan-
dem with dehydrogenases catalyzing extremely enantiose-
lective reduction reactions.[38-39] 
For oxidative reactions requiring regeneration of NAD 
(Pt from NAD(P)H, prior to the present invention, no 
universal cofactor regeneration system was known. Alcohol 
dehydrogenase (ADH) itself can be utilized to catalyze both 
the oxidative production reaction as well as the reductive 
regeneration reaction by adding isopropanol which is oxi-
dized to acetone, but such a scheme tends to be equilibrium-
limited and plagued by deactivation of ADH.[40] Both the 
ADH and the lactate dehydrogenase (LDH) systems [41] 
cannot take NADPH, in contrast to glutamate dehydroge-
nase (GluDH), which has been utilized to reduce a-keto-
glutarate to L-glutamate.[ 42,43] NADH oxidases from ther-
mophiles have been employed which regenerate NAD+ 
from NADH by reducing 0 2 to H20 2 .[44] 
What is needed are enzymes that regenerate NAD(P)H to 
oxidized cofactors NAD+ and NADP+ and synthesis meth-
ods that employ such enzymes alone or in coupled reactions. 
What is also needed are enzymes that perform the oxidation 
of NADH to NAD+ with the concomitant reduction of 
molecular oxygen to water as a solution to the cofactor 
regeneration problem from NADH to NAD+. Further, what 
Dehydrogenases and monooxygenases need nicotina-
mide-based cofactors, such as NAD+ and NADP+ or their 
reduced equivalents, NADH and NADPH, to function. Eco-
nomic use of dehydrogenases and cofactor necessitates 
cofactor regeneration.[16] Cofactor costs, for example, $90 
per gram for NAD+ have to be considered and having 
cofactors regenerated [17] would cut costs by the turnover 
number for such cofactors, between 100 and up to 600,000 
[18]. 
45 is needed are methods for efficiently isolating the enzymes. 
SUMMARY OF THE INVENTION 
The present invention comprises methods and composi-
Cofactor regeneration with alcohol dehydrogenases can 
50 tions comprising NAD(P)H oxidases (NOX). Compositions 
of the present invention comprise NOX that have activity in 
NAD+ regeneration and that have activity for both NAD+ 
and NADP+ regeneration. Additionally, the NOX show 
concomitant reduction of molecular oxygen to water. NOX 
be performed by using the same enzyme for in-situ substrate 
conversion and cofactor regeneration, usually employing 
isopropanol as co-substrate, as demonstrated with (S)-ADH 
from Thermoanaerobium brockii for both NADH and 
NADPH [19] and with (R)-ADH from L. brevis [20] for 
NADPH; this coupled-substrate approach, however, suffers 
from equilibrium limitations. The more common coupled-
system approach, employing a separate second enzyme for 
regeneration, has been developed for reducing oxidized 60 
cofactors, NAD+ or NADP+, to NADH or NADPH. By far 
the most successful regeneration enzyme is formate dehy-
drogenase (FDH) for regeneration to either NADPH [24-25] 
55 is expected to be produced easily and be available in 
sufficient amounts for large-scale use. Compositions of the 
present invention also include isolated NOX from Borrelia 
burgdorferi (BNOX) and from Lactobacillus sanfranciscen-
or NADH, the latter even up to industrial scale [20--23]. 
Other options include the use of glucose 6-phosphate dehy- 65 
drogenase [26] (to NADPH only) or of glucose dehydroge-
nase, GluDH [27-29]. For the opposite direction of regen-
sis (SFNOX). 
Further compositions comprise nucleic acids that encode 
the NOX, and recombinant plasmid vectors, and cells com-
prising the NOX-encoding nucleic acids. Such compositions 
include recombinant plasmid vectors and cells where the 
NOX-encoding nucleic acids are found alone or are found in 
combination with other enzyme-encoding nucleic acids. For 
example, compositions of the present invention comprise a 
cell comprising at least one plasmid comprising an enzyme-
US 7,163,815 B2 
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encoding nucleic acid, wherein in at least one encoding 
nucleic acid expresses at least one NOX of the present 
invention. The vectors of the present invention may be 
separate, under the control of one or more promoters, i.e., 
functioning like an individual plasmid, or may be interca-
lated with other vector constructs or genomic sequences. 
4 
methods, vectors and plasmids comprising the NOX nucleic 
acids, and cells comprising the enzymes or nucleic acids 
encoding the NOX proteins. Compositions also include 
products made in enzymatic reactions in which NOX par-
ticipates and enantiomer-enriches an unreacted racemate. 
SFNOX reacts with both NADH and NADPH, whereas 
BNOX reacts with NADH. Both enzymes reduce oxygen to 
water. As used herein, the term "NAD(P)H" means NADH 
Compositions of the present invention comprise whole 
cell catalysts, wherein the cells comprise NOX proteins 
and/or NOX-encoding nucleic acids and also comprise other 
enzymes or nucleic acids encoding such enzymes, so that all 
or part of a coupled enzymatic reaction can occur under the 
correct conditions. For example, a whole cell catalyst could 
comprise at least NOX and/or NOX-encoding nucleic acids 
and a dehydrogenase and/or dehydrogenase-encoding 
nucleic acids. 
10 or NADPH is the cofactor and, for enzymes capable of using 
both cofactors, means both NADH and NADPH. 
Compositions of the present invention further comprise 
nucleic acids and proteins encoded thereby that are derived 
15 
The methods of the present invention include isolation of 
NOX proteins, and methods for enzymatic reactions com-
prising NOX. As used herein, NOX is understood to include 
the NAD(P)H oxidases disclosed herein, including bacterial 
oxidases that use NADH and NADPH as a cofactor, the 
enzymes that were isolated from Borrelia burgdorferi 
(BNOX) and from Lactobacillus sanfranciscensis, any 
by mutation or alteration of the nucleic acids taught herein. 
Such mutated sequences encode proteins that have NAD 
(P)H activity and are used in the vectors, plasmids, con-
structs and whole cell catalysts taught herein. Additionally, 
such mutated sequences are contemplated in the methods 
steps taught herein, for example, in isolating or using the 
NOX sequences or proteins. 
20 recombinant sequences derived from bacterial oxidases that 
use NADH and NADPH as a cofactor and those found in 
Borrelia burgdorferi (BNOX) and in Lactobacillus sanfran-
ciscensis (SFNOX) and recombinant proteins expressed by 
those sequences in heterologous hosts, and any nucleic acid 
or amino acid variants with the oxidase activity of SFNOX 
and BNOX, and any mutants of bacterial oxidases that use 
NADH and NADPH as a cofactor and those found in 
Borrelia burgdorferi (BNOX) and in Lactobacillus sanfran-
Methods of the present invention comprise methods for 25 
isolating NOX from cells and methods for producing recom-
binant NOX from cells. Novel methods for isolation ofNOX 
from cells are provided herein that has utility for large-scale 
production of such enzymes. Methods for producing a 
recombinant NOX comprise cultivating a cell containing a 
construct comprising NOX encoding nucleic acid, and col-
lecting the NOX produced by the cell. 
30 ciscensis or nucleic acids thereof. 
The present invention also comprises methods of use of 
the NOX described herein in enzymatic reactions, and 
compositions of the products of such reactions. Some enzy- 35 
matic reactions contemplated by the present invention com-
prise methods of producing one or more chiral enantiomer-
enriched organic compounds in reactions comprising one or 
more NOX. Such enzymatic reactions may be performed in 
in vitro systems or in in vivo, living cell systems. 40 
BRIEF DESCRIPTION OF THE DRAWINGS 
In general, NADH oxidases (E.C. 1.6.-.-) catalyze the 
oxidation of NADH by simultaneously reducing molecular 
0 2 to either hydrogen peroxide, H20 2 , in a two-electron 
reduction (reaction 2), or directly to water in a four-electron 
reduction (reaction 3). 
(2) 
2NADH+02+2H.2NAD+ +2H20 (3) 
NADH oxidases contain a second cofactor, presumably 
covalently bound FAD, as evidenced by the consensus 
sequence GXT(HS)AG near the N-terminus, and are wide-FIGS. lA and lB are schematic drawings of enzyme 
reactions of NOX. 
FIG. 2A-2F are sequence comparisons for BNOX (A-C) 
and SFNOX (D-F). 
FIG. 3A-3C are graphs of the kinetics of SFNOX and 
BNOX with NAD(P)H cofactor in air-saturated solution at 
pH 7 and 30° C. 
45 spread among different, evolutionary distinct organisms, 
such as humans, vertebrates, plants, Drosophila and differ-
ent strains of bacteria. Bacteria harbor both H2 0 2 -forming 
and H20-forming NADH-oxidases. Owing to the deactiva-
tion of almost all proteins upon the exposure to H2 0 2 , the 
FIG. 4 is a graph showing activity-pH-profile of L. 
sanfranciscensis NADPH oxidase 
FIG. 5 is a graph of the standard curve for selective ion 
monitoring ofphenylethanol c• mass 122) acetophenone c• 
mass 120) 
DETAILED DESCRIPTION OF THE 
INVENTION 
50 H2 0-forming enzymes are superior as biocatalysts. Addition 
of catalase could potentially destroy the H2 0 2 formed, 
however, catalase itself features a very high KM-value of 1.1 
M [ 45], so that the enzyme is not particularly active at low 
H2 0 2 concentrations. Thermophilic bacteria usually only 
55 feature peroxide-producing NADH oxidases, which, despite 
their superior stability, renders them unfavorable for cata-
lytic purposes. Water-producing NADH-oxidases can be 
found in various organisms, such as Streptococcus, Entero-
coccus, Lactobacillus, Mycobacterium, Methanococcus, or 
60 The present invention comprises compositions and meth-
ods comprising novel NAD(P)H oxidases (NOX) from 
bacterial sources, and is particularly directed to SFNOX and 
BNOX. In summary, the compositions comprising NOX of 
the present invention include isolated enzymes, recombi-
nantly produced enzymes, nucleic acids encoding the NOX, 65 
NOX sequences, proteins and recombinant constructs 
wherein the altered sequences are derived by mutational 
Leuconostoc. These organisms can contain both water- as 
well as peroxide-producing enzymes. 
Various H2 0-producing NADH-oxidases have been 
found and described in the literature (see Table 1). None of 
them, however, has been characterized with respect to all of 
the properties relevant to use as a biocatalyst. In most cases, 
kinetic properties have not been reported. 
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6 
leaving a highly enantiomer-enriched unreacted optical anti-
pode of the original molecule, such as an alcohol. Dehy-
drogenases are capable of very specific enantiomeric selec-
tion and are used to prepare enantiomerically pure alcohols, 
hydroxy acids and amino acids as well as the corresponding 
ketones and keto acids. The dehydrogenase reaction requires 
the regeneration of the NADH or NADPH for cofactor 
activity, and thus, the NOX of the present invention have 
utility in coupled reactions with dehydrogenases including, 
10 but not limited to, alcohol dehydrogenase, lactate dehydro-
genase and amino acid dehydrogenase. Products from such 
reactions include the resolution of racemic mixtures, such 
resolution dependent on the selectivity of the dehydrogenase 
used, and resulting in the unreacted racemate from the 
15 original racemic mixture, and the product of the enzyme 
reaction. For example, from a racemic mixture of an R/S-
alcohol, in a reaction with an S-alcohol dehydrogenase, the 
resulting products are the unreacted enantiomer, the R-al-
cohol, and the resulting product, e.g, a ketone. 
The NOX of the present invention are important in 
synthesis methods comprising enzyme reactions where the 
reactants have one or more chiral centers. An embodiment of 
the present invention comprises methods for enzyme reac-
tions, comprising reacting at least one enzyme selective for 
Sequence analysis of the water-producing enzymes in all 20 
the organisms listed above reveals the same highly con-
served cysteine residue, compared to a rather modest overall 
sequence similarity. This suggests that all these flavoproteins 
constitute a distinct class of FAD-dependent oxidoreduc-
tases, different from others such as glutathione reductase and 
thioredoxin reductase. Other properties of the enzymes 
listed above are similar: the molecular weight of the subunit 
hovers around 50 kD, all enzymes are dimers and contain 1 
FAD per subunit, and all are inactivated by hydrogen 
peroxide. 
25 one enantiomer of at least one chiral center of a compound 
with one or more chiral centers, with a reactant composition 
comprising the compound with one or more chiral centers, 
wherein the at least one enzyme requires a nicotinamide-
based cofactor, and reacting the nicotinamide-based cofactor 
30 with one or more of the NOX of the present invention. In 
such methods where NAD+ is the cofactor, both SFNOX 
and BNOX individually or in combination could be used. In 
such methods where NADP+ is the cofactor, bacterial oxi-
dases that use NADH and/or NADPH as a cofactor, such as 
SFNOX, could be used. Bacterial oxidases that use NADH 
The present invention comprises compositions compris-
ing NOX and methods of making and using NOX, wherein 
the NOX comprise bacterial oxidases that use NADH and 
NADPH as a cofactor, and NOX that were isolated from 
Borrelia burgdorferi (BNOX) and from Lactobacillus san-
franciscensis, (SFNOX). As NAD(P)H oxidases, both 
BNOX and SFNOX function to regenerate NAD+, (See 
FIG. lA) and SFNOX has both NAD+ and NADP+ regen-
eration activity (See FIG. lB). The ability of SFNOX to 
oxidize both cofactors renders it an extremely useful catalyst 
for coupled enzymatically-catalyzed oxidations. The present 
invention comprises bacterial oxidases that regenerate both 
NADP+ and NAD+. The present invention comprises novel 
NAD(P)H oxidases that reduce oxygen directly to water, 
which also makes them useful in coupled enzymatic reac-
tions. 
The NOX of the present invention participate in reactions 
where there is a complete conversion of one of the enanti-
omers in a racemic mixture, such as an alcohol to a ketone, 
35 and/or NADPH as a cofactor, including SFNOX, could be 
also used alone in methods where NADP+ and NAD+ are 
cofactors, as well as combinations of enzymes, such as 
bacterial oxidases that use NADH and NADPH as a cofac-
tor, SFNOX and BNOX could be used in reactions where 
40 NAD+ and NADP+ are cofactors for enzymes in the reac-
tions. 
Embodiments of the present invention comprise isolated 
bacterial oxidases that use NADH and NADPH as a cofac-
tor. Embodiments of the present invention also comprise 
45 SFNOX (SEQ ID NOs 2, 4 and 6) and BNOX (SEQ ID NOs 
8, 10 and 12). The present invention also comprises nucleic 
acids of SFNOX (SEQ ID NOs 1, 3 and 5) and BNOX (SEQ 
ID NOs 7, 9 and 11). 






































































































































































































































































































SEQ ID NO.: 12 BNOX K6 















SFNOX and BNOX disclosed herein only share a modest 
32% amino acid sequence identity in between themselves 
and only 34% identity to the NOXs of either Enterococcus 
faecalis [48] or Streptococcus mutans [50], except for 55% 
between SFNOX and E. faecalis. The NOX coding genes 
from Borrelia burgdorferi (BNOX) and Lactobacillus san-
franciscensis (SFNOX) were isolated from the genomic 
DNA using gene specific primers derived from the coding 
sequence, SEQ. ID. NO.: 13-16. 
45 identity of 32%. The consensus sequences are the FAD-
binding site motif GXT(H/S)AG in position 8-14 (counted 
from the BNOX N-terminus), the putative catalytic cysteine 
residue in position 42, and the NAD-binding site GXGYIG 
50 
in positions 156-161. Alignment with the sequences of the 
NADH oxidases of Enterococcus faecalis [48] and Strepto-
coccus mutans [50] demonstrated at most 34% identity 
between any two including the two novel proteins, except 
for 55% between SFNOX and the enzyme from E. faecalis. 
In FIG. 2A-2C, the complete nucleotide sequences of 
BNOX, BNOXKl and BNOXK6 (SEQ ID NO.: 7, 9 and 11) 55 
as well as the respective deduced amino acid sequences 
(SEQ ID NO.: 8, 10 and 12) are shown. The nucleotide 
sequences are compared to the annotated sequence available 
The present invention also comprises nucleic acids that 
hybridize under stringent conditions with the single-
stranded (ss) nucleic acids or their complementary ss nucleic 
acids of the present invention. Stringent conditions are well 
known to those skilled in the art; see Sambrook et al., 
(Molecular Cloning, A Laboratory Manual, Cold Spring 
Harbor Laboratory Press (1989), 1.101-1.104). Stringent 
conditions are established by conditions such as salt con-
centrations, temperature and amount of time for washing of 
the hybridized nucleic acids. For example, conditions 
in the data bank, BNOX. In FIG. 2D-2F, both nucleotide 
(SEQ ID NO.: 1, 3 and 5) and deduced amino acid sequences 60 
(SEQ ID NO.: 2, 4 and 6) of SFNOX, SFNOXK2 and 
SFNOXK6 (SEQ ID NO.: 1, 3 and 5) are shown and are 
similarly compared to the annotated nucleotide sequence in 
the data bank, SFNOX. The decoration box indicates an 
exact match to the annotated sequences. 65 include washing of hybridized nucleic acids in 0.1 % SDS 
and 1.0x to 0.2xSSC, at temperatures from 50° C. to 68° C., 
for times of 0.5 to 1.0 hours. 
Comparison of the amino acid sequences between 
SFNOX and BNOX revealed a rather modest sequence 
US 7,163,815 B2 
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The present invention also comprises protein and nucleic 
acid sequences that exhibit a homology (exclusive of natural 
degeneration) greater than 80%, preferably greater than 
90%, 91 %, 92%, 93% or 94%, more preferably greater than 
95% or 96%, and most preferably greater than 97%, 98% or 
99% with SEQ. ID. NO.: 1-16, provided that the enzymatic 
activity is retained or the purpose of the sequence is retained, 
e.g. coding for a protein having this specific enzymatic 
activity or a protein fragment having a particular binding 
capability or immunogenic capability. Homology is defined 
10 
by the equation H(%)=[1-V/X]x100, where His homology, 
22 
sequences having at least all or a portion of SFNOX (SEQ. 
ID NO.: 1, 3 and 5) or BNOX (SEQ.ID NO.: 7, 9 and 11), 
or all or a portion of a combination of any of SEQ ID NO.: 
1, 3, 5, 7, 9 and 11. Such constructs may also have other 
sequences such as antibiotic resistance, the same or different 
promoters for SFNOX or BNOX, and other sequences 
known to those skilled in the art. 
Use of plasmids, vectors or constructs and different types 
of plasmids, vectors or constructs are well known in the art 
and the present invention contemplates inclusion of these 
uses and types with the sequences disclosed herein. Such art 
includes, but is not limited to, Sambrook, supra, or bro-
chures from companies such as Novagen, Promega, New 
England Biolabs, Clontech or Gibco BRL. Well known 
15 plasmids include pBTac (Roche Biochemicals), pKK-223 
(Stratagene) or pET (Novagen). 
X is the total number of nucleotide bases or amino acids of 
the comparison sequence, and V is the number of different 
nucleotide sequences or amino acids of the sequence of the 
comparison sequence. The term "nucleic acids coding for 
amino acid sequences" includes all nucleic acid sequences 
that could code for the amino acid sequences according to 
the degeneration of the genetic code. Additionally, nucleic 
acid sequences comprising modified, complexed or rare 
replacement nucleotides are comprised within the term 
nucleic acids. Nucleic acids comprise all types of nucleic 20 
acids, including single-stranded, double-stranded, nucle-
oproteins, sequences made with either deoxyribose or ribose 
(DNA or RNA) or mixtures thereof. Nucleic acids also 
comprise all corresponding interfering sequences, such as 
RNAi sequences, and antisense molecules. 
The compositions of the present invention also comprise 
combinations of all or a portion of SEQ ID NO.: 1, 3, 5, 7, 
9 and 11 with other nucleic acid sequences to encode 
chimera proteins, or the nucleic acids of NOX combined 
with proteins or attached to solid supports such as beads. 
Such chimera proteins or other combinations may or may 
not retain the enzyme activity of SFNOX and/or BNOX. For 
example, a nucleic acid construct that codes for a chimera 
In other embodiments, the present invention comprises 
primers for producing the gene sequences disclosed herein, 
25 
protein is constructed from SEQ. ID NO.: 1 and sequences 
for an antibody protein or binding fragment thereof. Such a 
chimera is used in antibody labeling experiments. 
for example, by amplification using methods known to those 
skilled in the art such as polymerase chain reaction. The 
primers include the sense and antisense primers coding for 
30 the corresponding amino acid sequences. Suitable primers 
may in principle be obtained by methods known to the 
person skilled in the art. The discovery of primers according 
to the invention is carried out by comparison with known 
DNA sequences or by translation of the visually detected 
amino acid sequences into the codon of the organism under 35 
consideration (e.g. for Streptomyces: Wright et al., Gene 
1992, 113, 55-65). Common features in the amino acid 
sequence of proteins of so-called superfamilies are also of 
use for this purpose (Firestine et al., Chemistry & Biology 
1996, 3, 779-783). Further information relating to the above 40 
may be found in "Oligonucleotide synthesis: a practical 
approach", edited by M. J. Gait, IRL Press Ltd, Oxford 
Washington D.C., 1984; PCR Protocols: A guide to methods 
and applications, edited by M.A. Innis, D. H. Gelfound, J. 
J. Sninsky and T. J. White. Academic Press, Inc., San Diego, 45 
1990. The following primers are most preferred: Restriction 
sites used are underlined. 
Primer Sequences: 
N- and C-terminal primers for L. sanfranciscensis 
The present invention also comprises compositions com-
prising the NOX enzymes disclosed herein that include 
immobilization of the enzymes on heterogeneous substrates. 
For example, the enzymes may be immobilized or attached 
to other proteins, through methods such as chemical linking 
of the proteins, attached to inert substrates such as microtiter 
plates, chromatography materials, balls, beads or other sub-
stances. The invention contemplates the use of such immo-
bilized enzymes in methods of synthesis, measurement, 
analysis or other methods wherein enzymes are used. These 
methods for immobilizing and using such immobilized 
enzymes are known to those skilled in the art. 
The compositions of the present invention also comprise 
antibodies and other specific binding partners, such as 
substrates, of SFNOX and BNOX, and immunogenic 
epitopes thereof. Such antibodies may be polyclonal or 
monoclonal, and include fragments such as Fab, FC, heavy 
chains, light chains, constant, variable, or hypervariable 
fragments or regions, and any type of antibody include but 
are not limited to IgM, IgG, IgA, IgD, and IgE. 
The compositions of the present invention also contem-
plate the inclusion of any cofactors, metals or other com-
SEQ ID N0.:135' gcg c gaattc atg aaa gtt att sanfranseco, 
gta gta ggt tgt act 3' 
Tm 67 .2° C. 
SEQ ID N0.:145' gcg c aagctt tta ttt atg tgc Sanfranashind, Tm 62.8° C. 
ttt gtc age ttg tgc 3' 
N- and C-terminal primers for B. burgdorferi 
SEQ ID N0.:155' gcg c gg ate cat gat gaa aat Borrnoxs, 
aat aat tat tgg ggg 3' 
SEQ ID N0.:165' gcg c aa get t ct att tgg cag Borrnoxas, 
cat tgc cag caa tat t 3' 
Tm 69 .5° C. 
Tm 70.6° C. 
The compositions of the present invention comprise vec- pounds or molecules necessary for activity or stability of the 
tors, plasmids or constructs comprising one or more of the 
65 
NOX of the present invention. 
NOX of the present invention. The terms vectors, plasmids The present invention also comprises microorganisms 
or constructs are used interchangeably to mean nucleic acid comprising the nucleic acids disclosed herein, particularly 
US 7,163,815 B2 
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SEQ ID NO.: 1, 3, 5, 7, 9 and 11. The microorganisms in 
which the nucleic acids are cloned are useful for propagation 
and production of a sufficient amount of the recombinant 
enzyme or enzymes. The methods for cloning, propagating 
and producing recombinant proteins in cellular systems are 
well known in the art. Examples of such microorganisms 
include, but are not limited to, prokaryotes or eucaryotes, 
such as Pseudomonas, Streptomyces, Arthrobacter, Bacillus, 
Staphylococcus, Enterococcus, especially E. coli, Candida, 
Hansenula, Pichia and baculovirus systems. Plasmids, vec-
10 
tors or constructs containing the gene constructs of 
SEQ.ID.NO.: 1 and/or 3 are cloned into host organisms, 
such as those above. 
The nucleic acids disclosed herein that code for the 
NAD(P)H oxidase (NOX) as described herein, are prefer-
ably suitable for the production of whole-cell catalysts. The 15 
invention provides a whole-cell catalyst containing a cloned 
gene for a dehydrogenase and a cloned gene for an NAD 
(P)H oxidase. The whole-cell catalyst according to the 
invention should contain an NAD(P)H oxidase (NOX), 
preferably a bacterial oxidase that can regenerate NAD+ and 20 
NADP+. More preferably, the NAD(P)H oxidase is one or 
more of the NOX disclosed herein and coded for by SEQ ID 
NO.: 1, 3, 5, 7, 9and11. Theproductionofsuchan organism 
is known to the person skilled in the art (PCT/EP00/08473; 
PCT/US00/08159). 25 
The advantage of such an organism is the simultaneous 
expression of at least two different enzymes, and then only 
the whole cell catalyst recombinant organism is used for the 
enzymatic reaction. In order to match the expression of the 
enzymes with respect to their reaction rates, the coding 30 
nucleic acids may be carried on various plasmids having 
different copy numbers and/or promoters of different 
strengths may be used. In one embodiment, the enzymes are 
encoded on plasmids with similar copy numbers in a host 
cell; and/or under the control of promoters of similar 35 
strength. With enzyme systems matched in this way there is 
advantageously no accumulation of a possible inhibiting 
intermediate compound( s ), and the reaction under consid-
eration may proceed at an optimal overall rate. This is 
described in PCT/EP00/08473; and Gellissen et al., Appl. 40 
Microbial. Biotechnol. 1996, 46, 46-54. 
Methods of the present invention comprise methods for 
growing and isolating NOX proteins, particularly bacterial 
oxidases capable of regenerating NAD+ and NADP+. One 
embodiment comprises growing host organisms, Lactoba- 45 
cillus sanfranciscensis or Borrelia burgdorferi, and isolating 
the NOX enzyme by methods known to those skilled in the 
art, such as ammoniUlll or acid precipitation, or chromatog-
raphy, and other protein purification techniques. An embodi-
ment comprises growing bacteria and isolating bacterial 50 
NOX that are capable of regenerating NAD+ and NADP+. 
Another embodiment comprises growing and isolating 
recombinant NOX proteins. 
The nucleic acids according to the invention can be used 
for the production of recombinant (rec) NAD(P)H oxidase, 
24 
which is included herein in the term NOX. Recombinant 
techniques known in the art can be used to produce the 
enzymes described herein in an amount sufficient for an 
industrial process from host cells carrying the nucleic acids 
encoding the enzyme. The production of the rec-enzymes 
according to the invention is carried out by genetic engi-
neering processes as described in, for example, Sambrook 
supra, Balbas P & Bolivar F. 1990; Design and construction 
of expression plasmid vectors in E. coli, Methods Enzymol-
ogy 185, 14-37; Vectors: A Survey of Molecular Cloning 
Vectors and Their Uses. R. L. Rodriguez & D. T. Denhardt, 
Eds: 205-225). With regard to the general procedure (PCR 
and fusion PCR, inverse PCR, cloning, expression etc.), 
reference may be made to the following literature and the 
references cited therein: Riley J, Butler R, Finniear R, Jenner 
D, Powell S, Anand R, Smith J C, Markham AF (1990). A 
novel, rapid method for the isolation of terminal sequences 
from yeast artificial chromosome (YAC) clones. Nucl Acids 
Res. 18, 8186; Triglia T, Peterson MG, Kemp DJ (1988). 
A procedure for in vitro amplification of DNA segments that 
lie outside the boundaries of known sequences. Nucleic 
Acids Res. 16, 8186; Sambrook J, Fritsch E F, Maniatis T 
(1989). Molecular Cloning. Cold Spring Harbour Labora-
tory Press; Vectors: A Survey of Molecular Cloning Vectors 
and Their Uses. R. L. Rodriguez & D. T. Denhardt, II. 
The bacterial oxidase enzymes described herein may be 
used in the free form as homogeneously purified com-
pounds, or as enzymes produced by recombinant technol-
ogy. Furthermore the enzymes may also be employed as a 
constituent of an intact host organism or in conjunction with 
the macerated cell mass of the host organism purified to an 
arbitrarily high degree. It is also possible to use the enzymes 
in immobilized form (Bhavender P. Sharma, Lorraine F. 
Bailey and Ralph A. Messing, "Immobilisierte Biomateri-
alien-Techniken undAnwendungen", Angew. Chem. 1982, 
94, 836-852). The immobilization is preferably carried out 
by lyophilisation (Dordicket al. J.Am. Chem. Soc. 194, 116, 
5009-5010; Okahata et al. Tetrahedron Lett. 1997, 38, 
1971-1974; Adlercreutz et al. Biocatalysis 1992, 6, 
291-305). It is most particularly preferred to carry out the 
lyophilisation in the presence of surfactants such as aerosol 
OT, polyvinylpyrrolidone, polyethylene glycol (PEG) or 
Brij 52 (diethyleneglycolmonocetyl ether) (Goto et al. Bio-
technol. Techniques 1997, 11, 375-378). The use as CLECs 
is also possible (St Clair et al. Angew Chem Int Ed Engl 
2000 January, 39(2), 380-383). 
The present invention comprises methods for isolating 
NOX. One embodiment comprises methods of isolation 
comprising the purification table shown in Table 2. The 
procedure results in a strong single prominent band at 50 
kDa in the protein gel analysis, is scalable, and results in 
high yields. Acid precipitation as the first resolution elimi-
nates buffer/salt exchanges and leaves the final protein 
preparation in stabilizing levels of ammonium sulfate. [63] 
TABLE 2 
Purification table resulting in scalabililJ: and high yield 
Step 
Lysate (pH 5.0) 











Specific Yield Purification 
Activity (U/mg) (%) factor LU 
29.7 100.0 1.0 4329.3 
51.8 67.3 1.7 2912.7 
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TABLE 2-continued 
Purification table resulting in scalability and high yield 
Vol Activity Protein Specific Yield Purification 
















*estimated theoretical yield for entire preparation. 
Another embodiment comprises the steps in a different trifugation followed by other techniques such as displace-
sequence (lysate---45% ammonium sulfate precipitation- ment chromatography, sizing chromatography, affinity chro-
15 
acid precipitation (pH 5, 30° C.)-Q-Sepharose FF) which, 
in one experiment, resulted in the same specific activity to 
within 0.5% The yield of this alternative purification 
sequence was 33.6%. 
Step 
matography, molecular sieving, cofactor binding, or other 
techniques that isolate the NOX from the solution. These 
isolation methods are well known in the art and all appli-
cable methods are contemplated as part of the present 
invention. 
TABLE 3 
Purification of NADH oxidase from L. sanfranciscensis 
Activity Protein Specific 









661.9 23,443 1.0 




Displacement 136.2 0.6 220.9 26.2 27.75 6,131 6.2 
Source 30Q 
Another embodiment for isolation of NOX comprises 
displacement chromatography after dialysis and acid pre-
cipitation, (like that described above). The displacer was 
naphthalene-1,3,6-trisulfonic acid, which provides for a 
method of isolation that can be scaled-up for industrial use. 
As the results in Table 3 reveal, purity in excess of 95% at 
26% yield was achieved with a specific activity of 221 U/mg 
protein. The highly pure and active fractions can then be 
pooled and stored in 45% ammonium sulfate solution at 4° 
C. to preserve the enzyme's stability. Displacement chro-
matography generally improves at higher loadings [52] and 
the novel displacer, naphthalene-1,3,6-trisulfonic acid, is an 
inexpensive reagent in contrast to many other reported 
displacers [53]. 
A method for isolating NOX comprises, a) precipitating 
with an acid solution of pH 4.5 to 6.0, a bacterial cellular 
lysate; and b) isolating NOX proteins from the solution ofb) 
after precipitation occurs. In general, precipitation in an acid 
solution inactivates most proteins in the cellular lysate, but 
not the NOX proteins. Precipitation begins as soon as the 
lysate is placed in the acidic solution. The range of pH of the 
acidic solution is from approximately 4.5 to approximately 
6.0, preferably pH 4.5 to 5.5, and more preferably pH 5.0. 
The time for precipitation can be in a range from minutes to 
hours, including 10 minutes to 24 hours. Precipitating activ-
ity can occur at the same time as other activities such as salt 
removal in dialysis systems. The precipitated material con-
tains inactivated proteins and the resulting solution contains 
the NOX proteins. Isolation of the NOX protein from the 
solution can be accomplished any number of different meth-
ods known to those skilled in the art. For example, NOX 
may be isolated by centrifugation of the solution, or cen-
35 
The ability of bacterial oxidases, such as SFNOX, to 
oxidize both cofactors, NADPH and NADH, renders such 
enzymes as an extremely useful catalyst for coupled enzy-
matically-catalyzed oxidations. To demonstrate the regen-
40 eration to either NAD+ or NADP+ by NAD(P)H oxidase 
SFNOX, the enzyme was combined with (R)-ADH from L. 
brevis to produce acetophenone and (S)-phenylethanol from 
racemic (RS)-phenylethanol. (R)-ADH from L. brevis [54] 
was picked for the following advantages: i) (R)-l-phenyle-
45 thanol is a very good substrate, on a par with the best 
substrates of the enzyme, ii) whereas the wildtype is mainly 
NADPH-dependent, the G37D mutant strongly prefers 
NADH over NADPH [55], albeit at reduced specific activ-
ity; iii) lastly, (R)-ADH from L. brevis has been explored 
50 extensively for the enzymatic generation of several pharma-
ceutically interesting chiral alcohols [56-59,25]. 
In experiments described herein, after 12 h, nearly com-
plete conversion (maximally 50% of racemic phenyl ethanol) 
was achieved in all but the case of the G37D mutant ADH 
55 with NAD+. The very high KM"value of the mutantADH for 
NAD+ in comparison with the wildtype for NADP+ is a 
possible explanation for the lower rate (less than v max) and 
thus lower conversion after 12 hr. The number of turnovers 
([acetophenone]/[cofactor]) of up to more than 100 clearly 
60 demonstrates catalysis by both enzymes involved. 
Methods of the present invention comprise coupled enzy-
matic reactions wherein bacterial oxidases, including but not 
limited to, SFNOX, provide both NAD+ and NADP+ to one 
or more enzymes. An embodiment of methods of using 
65 bacterial oxidases, including but not limited to, SFNOX, 
comprises use in analytical determinations such as in mea-
suring the total amount of reducing equivalents from NAD+ 
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and NADP+ in a cell by measuring the reactions of bacterial 
oxidases, including but not limited to, SFNOX, and NAD/ 
NADP. Such measurements can be important to estimate the 
ability of a cell to achieve reduction of a given substrate. The 
reducing equivalent amount can provide an identifying 
characteristic of a cell or cell types. For example, such 
measurement could differentiate between normal, precan-
cerous and cancerous cells, or between normal cells and 
cells entering apoptosis, or between different cellular types. 
Another embodiment comprises using bacterial oxidases, 10 
including but not limited to, SFNOX as a standard in 
NAD/NADP experiments. 
One embodiment of the present invention comprises 
methods and compositions comprising recombinant NOX 
and nucleic acids encoding recombinant NOX that have 15 
been altered from genomic or recombinant sequences by 
mutation. One method comprises the production of 
improved rec-NOX and rec-NOX obtained thereby or 
nucleic acids coding therefor, starting from the nucleic acids 
according to the invention coding for an NAD(P)H oxidase 20 
(NOX), such method comprising, 
a) mutating nucleic acids, 




b) cloning the nucleic acids obtained from a) in a vector, 
plasmid or construct; and 
c) isolating the proteins expressed. 
This process may be executed once or any desired number 
of times in succession. Preferably, the mutated nucleic acids 
code for proteins having a property different from the 
proteins encoded by the nucleic acids disclosed herein, more 
preferably, the mutated rec-NOX have enhanced desired 
properties such as faster cofactor turnover or more stability 
in reaction conditions. 
Embodiments of mutations of the present invention com-
prise individual amino acid substitutions, and its concomi-
tant changes in the nucleic acid sequence. Preferred embodi-
ments comprise mutated sequences comprising at least a 
substitution at position 42 of SFNOX. For example, muta-
tions of position of 42 of C to S, C to M, C to A and C to 
F. (for example, SEQ ID NO. 17-20), and the nucleic acids, 
including degenerate bases, that encode such amino acids. 
Embodiments of the present invention comprise other amino 
acid substitutions at this site, and such mutations include 
substitution or unnatural amino acids, such as homoserine, 
























SEQ ID NO. 19 




























Embodiments of mutations of the sequences and resulting 
proteins disclosed herein also include, but are not limited to, 
substitutions at other sites, insertions, deletions, additions 
and reversions, changes due to recombination of NOX 
sequences or sequences comprising NOX sequences with 
other nucleic acids, and other mutations known to those 
skilled in the art. 
The procedure for mutating the enzymes of the present 
invention by mutagenesis methods has long been known to 
the person skilled in the art. As mutagenesis methods there 
may be used all methods for this purpose available to the 
person skilled in the art. In particular these include satura-
tion mutagenesis, random mutagenesis, shuffling methods as 
well as site-directed mutagenesis (Eigen M. and Gardinger 
W. (1984) Evolutionary molecular engineering based on 
RNA replication. Pure &Appl. Chem. 56(8), 967-978; Chen 
& Arnold (1991) Enzyme engineering for nonaqueous sol-
vents: random mutagenesis to enhance activity of subtilisin 
E in polar organic media. Bio/Technology 9, 1073-1077; 
Horwitz, M. and L. Loeb (1986) "Promoters Selected From 
Random DNA-Sequences" Proceedings Of The National 
Academy Of Sciences Of The United States Of America 
83(19): 7405-7409; Dube, D. and L. Loeb (1989) "Mutants 
Generated By The Insertion Of Random Oligonucleotides 
Into The Active-Site Of The Beta-Lactamase Gene" Bio-
chemistry 28(14): 5703-5707; Stemmer PC (1994). Rapid 
evolution of a protein in vitro by DNA shufl.ling. Nature. 
45 370; 389-391 and Stemmer PC (1994) DNA shuffling by 
random fragmentation and reassembly: In vitro recombina-
tion for molecular evolution. Proc Natl Acad Sci USA. 91; 
10747-10751). 
The new nucleic acid sequences that are obtained are 
50 cloned according to the methods known to those skilled in 
the art in a host organism and the expressed enzymes are 
detected and then isolated using suitable screening methods 
(Roberts J., Stella V. J. and Decedue C. J. (1985) A colori-
metric assay of pancreatic lipase: rapid detection of lipase 
55 and colipase separated by gel filtration. Lipids 20(1): 42-45; 
Pratt R. F., Faraci W. S. and Govardhan C. P. (1985) A direct 
spectrophotometric assay for D-alanine carboxypeptidases 
and for the esterase activity of beta-lactamases. Anal. Bio-
chem. 144(1): 204-206; Bruckner, H., R. Wittner, and H. 
60 Godel (1991) Fully automated high-performance liquid 
chromatographic separation of DL-amino acids derivatized 
with o-Phthaldialdehyde together with N-isopropyl-cys-
teine. Application to food samples). 
The present invention also comprises using NAD(P)H 
65 oxidase (NOX), bacterial oxidases with NAD+ and NADP+ 
regeneration activity, SFNOX, BNOX and the proteins 
encoded by SEQ ID NOs 1-12 and 17-20 and any mutations 
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thereof, for the production of chiral enantiomer-enriched 
organic compounds such as, for example, alcohols or amino 
acids, in coupled enzymatic reactions. Such compounds are 
useful in pharmaceutical preparations, in agricultural uses, 
for food, and crop protection industries as well as building 
blocks for novel compounds not accessible through fermen-
tation and for asymmetric synthesis templates. Embodi-
ments of such methods comprise a method of organic 
synthesis, comprising, reacting a bacterial NAD(P)H oxi-
dase with NADH or NADPH in a coupled enzyme reaction, 10 
and isolating the products of the reaction. Such methods of 
use include the synthesis of enantomerically-enriched chiral 
compounds, synthesis of chiral compounds, synthesis of 
physiologically effective compounds that are used in treat-
ments of humans, animals, plants, insects, microbiological 15 
organisms, and other eukaryotes and prokaryotes. For 
example, compounds are produced that are effective in 
treatment of humans and other animals for hypertension, 
diabetes, cardiovascular disease, cancer, and conditions 
involving the brain, eyes, heart, lungs, liver, immune system, 20 
urinary organs, reproductive organs, integumentary system, 
nervous system and other conditions where pharmaceutical 
agents are effective. Compositions that are effective in such 
methods include compositions comprising at least a bacterial 
oxidase that regenerates NADP+ or NAD+, and preferably 25 
comprise at least a bacterial oxidase that regenerates 
NADP+ and NAD+. 
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poses an HBlOl strain (Stratagene, La Jolla) or M15 strain 
including the pREP4 plasmid (Qiagen, Hilden) was 
employed. These E. coli strains were grown at 30° C. under 
agitation for optimized expression levels. Ampicillin was 
added to the medium at a final concentration of 100 µg/ml 
to maintain selection pressure. To the M15 strain, 25 µg/ml 
kanamycin was added to maintain the additional helper 
plasmid. 
Plasmids used: for cloning and sequencing, target genes 
were cloned into pB!uescript (Stratagene, La Jolla); for 
expression either the pkk223-3 (Amersham) or pBTac2 
(Roche) were chosen. 
Example 2 
Manipulation and Amplification of DNA 
The nox DNA sequences were identified using a search of 
the NCBI Gene bank (Accession files AB035801 for SFNOX 
and NC_001318 for BNOX). The corresponding specific 5' 
and 3' primers were synthesized at MWG Biotech (High 
Point, N.C.). Primer optimization was performed using a 
primer design program (webbased design, http:/genome-
www2.stanford.edu/cgi-bin/SGD/web-primer). The nox 
genes from L. sanfranciscensis and B. burgdorferi were 
amplified using PCR and the gene-specific primers. Restric-
tion sites used are underlined. 
Primer Sequences: 
N- and C-terminal primers for L. sanfranciscensis 
5' gcg c gaattc atg aaa sanfranseco Tm 67.2° C. 
gtt att gta gta ggt tgt 
act 3' 
Unless otherwise defined, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art of molecular 30 
biology. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described herein. All publications, patent applica-
tions, patents, and other references mentioned herein are 
incorporated by reference in their entirety. In addition, the 
materials, methods, and examples are illustrative only and 
are not intended to be limiting. 
35 5' gcg c aagctt tta ttt 
atg tgc ttt gtc age ttg 
tgc 3' 
sanfranashindTm 62.8° C. 
The present application claims priority to U.S. Provisional 
Patent Application 60/399, 850, the entire contents of which 40 
are incorporated herein by reference. Additionally, the ref-
erences cited herein are each hereby incorporated by refer-
ence in its entirety. 
N- and C-terminal primers for B. burgdorferi 
5' gcg c gg ate c at gat borrnoxs Tm 6 9. 5 ° C. 
gaa aat aat aat tat tgg 
ggg 3' 
5' gcg c aa get t ct att 
tgg cag cat tgc cag caa 
tat t 3' 
borrnoxas Tm 7 0. 6 ° C. 
Having generally described this invention, a further 
understanding can be obtained by reference to certain spe- 45 
cific examples. The examples are not intended to limit, and 
should not be interpreted as limiting, the scope of what the 
inventors regard as their invention. 
Amplification of the target DNA was performed using the 
protocol from the failsafe PCR kit (Epicentre, Madison). 
Twelve reactions using 12 different buffers were set up and 
tested for optimal conditions. Setting up the PCR reactions 
EXAMPLES 
Example 1 
Bacterial Strains, Media and Growth Conditions 
The genomic DNA from Borrelia burgdorferi (ATCC 
35210) and the strainLactobacillus sanfranciscensis (ATCC 
27651) were obtained from ATCC and grown in MRS 
medium (Gibco) at pH 6.5 under facultatively anaerobic 
conditions at 30° C. in quiescent culture. For expression of 
wild-type NADH oxidase, the L. sanfranciscensis strain was 
grown in the same medium, but under aeration with 120 rpm 
in an Infors shaker at 30° C. 
Host strains of E. coli were grown in Luria-Bertani 
medium at pH 7.5 and 37° C., for cloning purposes or 
routine growth and plasmid production the host strain XL! 
blue (Stratagene, La Jolla) was used. For expression pur-
50 involved final DNA concentration of 100 ng (L. sanfranci-
scensis) and 3.4 ng (B. burgdorferi), 200 µM of each dNTP, 
10 µM of each primer and 1 U ofTaq polymerase (Epicentre, 
Madison) in a final volume of 25 µ!. To each of these 
reactions, 25 µl of each of the twelve doubly concentrated 
55 reaction buffer was added. DNA was amplified successfully 
for 30 cycles in an Eppendorf Gradient Thermocycler (Ep-
pendorf, Hamburg) using the following conditions: each 
cycle involved a denaturing step at 30 sec 94° C., an 
annealing step at 30 sec 60° C. or 68° C., and an extension 
60 step at 2 min 72° C. Of the final reaction mixture, 50 µl was 
analyzed on 1 % agarose gels stained with 0.05% ethidium 
bromide. Prior to any further use, these PCR products were 
gel purified using the gel extraction kit (Qiagen, Hilden). 
Amplification in PCR succeeded using the PCR failsafe 
65 kit (Epicentre, Madison) to yield products of the predicted 
size of 1335 bp for bnox and 1356 bp for sfnox in several of 
the 12 buffers provided with the kit. The primers were 
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designed to contain convenient restriction sites (EcoRl and 
HindIII for SFNOX and BamHl+HindIII as well for 
BNOX) at both ends to facilitate the following cloning step. 
DNA electrophoresis on a 1 % agarose gel demonstrates 
amplification of the nox genes under different PCR-buffer 5 
conditions. As expected, single bands in each lane were 
found at around the 1300 bp band for BNOX and between 
1300 and 1400 bp for the SFNOX. Depending on buffer 
conditions, strong or weak amplification was observed with 
both NOX genes. Each one of the strongest bands was cut 10 
out of the 1 % agarose gel and purified using the gel 
purification kit (Qiagen, Hilden). 
Both gene products as well as the pbluescript vector 




5 ml LBamp was inoculated with a colony and grown 
overnight at 37° C. Cells were harvested by centrifugation 
(10000 rpm, 5 min, Eppendorf centrifuge, Hamburg) and 
plasmid DNA was isolated following the manufacturer's 
protocol (Miniprep Spin Kit, Qiagen, Hilden). Plasmid DNA 
was eluted into 50 µl water and 5 µl were digested with the 
corresponding restriction enzymes at the sites used for 
cloning and ligating. 
Example 6 
Sequencing 
20 µg of plasmid DNA (using the pB!uescript vector) was 
sent off for sequencing using the same primers as for 
amplification in PCR. The templates were labeled with 
BNOX with BamHl and HindIII and SFNOX with EcoRl 15 
and HindIII. Following restriction, the genes and the vector 
were purified through gel electrophoresis and subsequent 
elution (gel purification kit, Qiagen, Hilden). Both genes 
were separately cloned into the pbluescript vector (Strat-
agene, La Jolla) and transformed into the E. coli XLl blue 
strain (Stratagene, La Jolla). Positive clones were screened 
using colony PCR and restriction analysis. 
20 Applied Biosystems' "BigDye Terminator v3.0 Cycle 
Sequencing Ready Reaction" Kit for 25 cycles. Excess dye 
terminator molecules were removed with Qiagen Dye-Ex 
Spin Colunms (Qiagen, Hilden). The samples were analyzed 
on the Applied Biosystems 3100 Genetic Analyzer (Perkin-
Nucleotide data corresponding to the 1335 bp of BNOX 
and 1356 bp for SFNOX, starting with ATG, were obtained 
through cycle sequencing using an ABI prism sequencer. 
Nucleotide sequence and deduced open reading frames are 
shown in FIG. 2. Sequencing templates were the pblue-
script-constructs. The open reading frame for both noxes is 
capable of encoding a protein with a molecular mass of 48.8 
kD for SFNOX and 48 kD for BNOX. SDS-PAGE of the 
proteins derived from the expressed genes exhibited a 
prominent band at around 45-50 kD. The GC content of the 
genes coding for BNOX and SFNOX are very low, 32% and 
37%, respectively, consistent with the range reported by 
Ross and Claiborne (1992).[48] 
Example 3 
Cloning 
25 Elmer-AB, Boston). 
Sequence analysis of both SFNOX and BNOX genes 
revealed differences when compared to the annotated nucle-
otide sequences derived from the NCBI databank (accession 
files AB035801 for SFNOX and NC_001318 for BNOX). 
30 Both fully sequenced SFNOX clones, SFNOXK2 and 
SFNOXK6, featured an amino acid change from alanine to 
valine at position 30 (A30V). SFNOXK6 showed an addi-
tional change from lysine to arginine at position 102 
(K102R). Both constructs, when overexpressed, showed 
35 comparable activity. Though not wishing to be bound by any 
particular theory, it is believed that position 102 does not 
diminish enzyme activity and that SFNOXK2 with its 
sequence difference in position 30 shows the correct 
sequence for a NADH oxidase from L. sanfranciscensis 
40 rather than the sequence annotated in the databases. 
Nox-specific DNA from L. sanfranciscensis was ligated 
into pB!uescript (Stratagene, La Jolla) using EcoRl (5') and 
HindIII (3') restriction sites and accordingly, nox from B. 
burgdorferi with BamH1(5') and HindIII (3') restriction 
sites. For all necessary ligations the Rapid Ligation kit 45 
protocol (Roche, Penzberg) was followed. The same pmol 
amounts of DNA were ligated, concentrations were calcu-
lated accordingly using the spectrophotometrically deter-
mined 260/280 nm ratio. Wildtype or mutant expression 
clones were constructed with the same restriction sites of 50 
Nox-L-sanfranciscensis (Lsfnox) into pkk223-3 (Amer-
sham, Piscataway, N.J.) and nox-B-burgdorferi (Bnox) into 
pBtac2 (Roche, Penzberg). Positive clones were tested either 
through colony PCR or restriction digest after plasmid 
preparation using the Miniprep Spin kit (Qiagen, Hilden). 55 
Example 7 
Expression of the nox Genes 
The pbluescript constructs were used to cut out the 
desired gene and subclone it into the expression vector 
pkk223-3 (Amersham) or pBTac2 (Roche), respectively. 
With this method no additional PCR was required and risk 
for additional PCR errors was avoided. Subcloning was 
successful using the Rapid DNA ligation kit (Roche) and the 
ligation was transformed into competent HB101 (Strat-
agene, La Jolla) or M15 E. coli strains (Qiagen, Hilden). 
Colonies formed were tested for successful incorporation 
through colony PCR. 
Two successful clones of each construct were expressed at 
37° C. and harvested after 4 h of IPTG induction 
(SFNOXK2 and SFNOXK6 for L. sanfranciscensis and 
BNOXKl and BNOXK6 for B. burgdorferi). Cell density 
Example 4 
Colony PCR 
Colonies of the transformation plate were picked and first 
transferred onto a master plate, then suspended into 50 µl of 
lysis buffer containing Triton-X-100 (20 mM Tris pH 8.5+5 
mM EDTA+1% Triton X-100). After denaturing at 95° C. 
for 15 min, the solution was vortexed for 10 seconds and 
then 5 µl of the extract was tested in PCR (total volume 50 
µl) using the gene specific primers. 
60 was equalized to an OD600 of 5.0 and then ultrasonicated in 
200 µl of 100 mM TEA pH 7 .5 buffer. Equal amounts of each 
fraction, soluble and unsoluble, induced and uninduced, 
were loaded onto a 12.5% SDS-PAGE. At 37° C., the 
SFNOXK6 clone demonstrates a high level of overexpres-
65 sion in the insoluble fraction, possibly owing to the addi-
tional mutation. BNOXKl does not show an overexpres-
sion, and the expression level of BNOXK6 is slightly lower 
US 7,163,815 B2 
35 
than that of SFNOXK2. In the case of SFNOXK2, the 
addition of helper plasmid pREP4 resulted in less uninduced 
expression when compared to the same clone without the 
helper plasmid. 
36 
solution was added. Enzyme reaction was followed for 1 
min, activity was calculated using an extinction coefficient E 
of NADH of 6.22 L/(mol-cm). 
Heterologous expression of the nox genes in E. coli was 5 
performed as follows: 5 ml starter LBamp cultures were 
inoculated with aliquots from frozen stock cultures contain-
ing either bnox-pBTac2 or sfnox-pkk223-3 and grown over-
night at 37° C. These starter cultures were used to inoculate 
200 ml cultures (1 % v/v) or 1 L cultures (1 % v/v), which 10 
were vigorously aerated until A600 reached 0.5-0.6, at which 
point the cultures were induced with 1 mM IPTG (final 
concentration) and protein expression was performed for 4 
Example 9 
Fermentation 
Production strains were grown in 5 ml cultures at 37° C. 
and 250 rpm in 15 ml disposable culture tubes to 1.0 OD 600 
nm in LB media+ 100 ug/ml ampicillin. One liter cultures of 
LB medium supplemented with 5 g/L glycerol were seeded 
with 1 ml of the starter culture and grown at 30° C. and 200 
rpm. Both baffled and unbaffled Fernbach shake flask were 
used for fermentation. When the cultures reached 1.0 OD h. Cells were harvested and pellets frozen away at -20° C. 
or used directly for enzyme activity assays. 15 600 nm the flask were induced by addition of0.5 mM IPTG 
and grown for an additional 3-4 hours. Additional ampicil-
lin, 200 µg/ml, was added at induction and every hour 
thereafter to maintain selection pressure on the culture. 
For SDS-PAGE, 5 ml cultures were grown up to A600 of 
0.5 and then induced with 1 mM IPTG for 4 h. Cells were 
harvested, resuspended in 200 µl TE50/50 (50 mM Tris, 50 
mM EDTA pH 8.0), and sonicated for 2x15 sec with ice 
cooling. Supernatant (representing the soluble fraction) was 20 
separated after centrifugation and the insoluble fraction was 
resuspended in 200 µl TE 50/50 and shortly sonicated (5 sec) 
When helper plasmids were present in the strains 50 µg/ml 
kanamycin was also added to the culture. Cultures were 
harvested by centrifugation at 5000 rpm in 1 L centrifuge 
containers (Beckman J2-M) and the resulting cell pellet was 
frozen at -80 C. to dissolve the pellet. 10% SDS sample buffer was added 
(10% Glycerol, 2% SDS, 0.063 M Tris/HCl pH 6.8, 0.1 % 
Bromphenolblue+either 10% ~-Mercaptoethanol or 75 mM 25 
DTT) and 30 µl analyzed on a 12.5% SDS-PAGE, stained 
with Coomassie blue (Pierce gel code staining solution, 
Pierce, Rockford, Ill.). Standard proteins used for molecular 
mass determination were obtained from New England 
Biolabs (Beverly, Mass.; broad range molecular weight 30 
markers, prestained). 
Example 10 
Purification of sfnoxK2 Enzyme 
Frozen cell pellets were thawed and resuspended in 10 ml 
of 100 mM potassium phosphate buffer pH 6.8+1 mM 
EDTA+5 mM DTT +5 mM spermine. The cell slurry was 
then sonicated with a Fisher Scientific 60 Sonic dismem-
brator for 6x2 minutes while floating the tube in ice water 
for cooling. The resulting lysate was centrifuged at 18,000 
Protein Gel Analysis 
Prior to SDS-PAGE, protein samples were diluted to 2 
mg/mL concentration in deionized water if the initial con-
centration was above 2 mg/mL. The 50 µL diluted samples 
were then mixed with 50 µL of 2x sample buffer composed 
of 125 mM Tris-HCl, pH 6.8, 4% SDS, 50% glycerol, 0.02% 
bromophenol blue, and 10% 2-mercaptoethanol. Mixed 
samples were incubated at 100° C. for 5 minutes and then 
placed on ice. 10 to 20 µL of the samples were loaded onto 
a 12% PAGEr™ Gold precast gel and run in a Hoefer SE260 
chamber at 125V for 2 hours (running buffer: 25 mM Tris 
base, 192 mM glycine, 0.1 % SDS) with chilling water 
circulating at 4° C. Molecular weight standards ProSieve® 
from BMA or Precision Plus Protein™ standards from 
Bio-Rad were added to lanes immediately adjacent to the 
sample lanes. 
Determination of Protein Concentration 
Protein concentration was determined by the Bradford 
method utilizing Coomassie Plus Protein assay reagent and 
pre-diluted protein assay standards-BSA (Pierce Chemical) 
for the calibration curve. Coomassie blue from Pierce 




Nox activity assay: Cell-free extracts of the recombinant 
sfnox and bnox E. coli strains were prepared using ultra-
sonication described above in 0.1 M TEA pH 7.5+5 mM 
DTT or ~-mercaptoethanol. Nox activities were assayed at 
30° C. in a total volume of 1 mL at 340 nm using the 
following conditions: in 0.1 M TEA pH 7.5 a final concen-
tration of 0.2 mM NADH was dissolved and 10 µl enzyme 
35 rpm in a Beckman J2-21M for 45 minutes at 4° C. The 
clarified lysate was then loaded into Spectra/Par® regener-
ated cellulose dialysis membrane tubing (60K MWCO) and 
dialyzed against 1 L of 45% ammonium sulfate+50 mM 
potassium phosphate buffer pH 6.8+1 mM EDTA+5 mM 
40 DTT. After four hours the sample was transferred to a second 
freshly prepared 45% ammonium sulfate solution. Follow-
ing an additional 8 hours of dialysis (overnight), the sample 
was centrifuged at 18,000 rpm for 15 minutes at 4 ° C. The 
resulting solution was transferred to a Pierce Slide-A-
45 Lyzer® dialysis cassette (!OK MWCO) and dialyzed versus 
20 mM 1-methylpiperazine buffer pH 5.0 and 30° C.+5 mM 
DTT. The sample was dialyzed versus a liter of buffer for 
two hours at 30° C. with stirring (200 rpm) on a digital 
magnetic stirplate/heater with a temperature probe to main-
50 tain the solution at 30° C. A buffer exchange was performed 
after one hour of dialysis. The sample was then transferred 
and centrifuged at 18,000 rpm for 15 minutes at 4° C. The 
resulting solution was then loaded onto a Amersham Phar-
macia HiPrep 16/10 Q FF colunm on anAKTA system at 4° 
55 C. A gradient separation was performed from 0 to 100% 1 
M NaCl with the running buffer 20 mM 1-methylpiperazine 
buffer pH 5 .0 at 4 ° C. 5 ml fractions were collected over the 
course of the run and the nine most active fractions were 
60 
pooled. 
A second purification protocol utilized 100 mM 1-meth-
ylpiperazine buffer pH 5.0 in the lysis buffer. Frozen cell 
pellets were thawed and resuspended in 10 ml of 100 
mM-methylpiperazine buffer pH 5.0+1 mM EDTA+5 mM 
DTT +5 mM spermine. The cell slurry was then sonicated 
65 with a Fisher Scientific 60 Sonic dismembrator for 6x2 
minutes while floating the tube in ice water for cooling. The 
resulting lysate was centrifuged at 18,000 rpm in a Beckman 
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J2-21M for 45 minutes at 4° C. The clarified lysate was then 
loaded into Spectra/Par® regenerated cellulose dialysis 
membrane tubing (60K MWCO) and dialyzed with 1 L of20 
mM 1-methylpiperazine buffer pH 5.0 at 35° C.+5 mM DTT. 
The sample was dialyzed versus 1 L of buffer for two hours 5 
at 35° C. with stirring (200 rpm) on a digital magnetic 
stirplate/heater with a temperature probe to maintain the 
solution at 35° C. A buffer exchange was performed after 
one hour of dialysis. The sample was then transferred and 
centrifuged at 18,000 rpm for 15 minutes at 4° C. The 10 
resulting solution was then loaded onto a Amersham Phar-
macia Mono-Q colunm on an AKTA system at 4 ° C. A 
gradient separation over 10 colunm volumes was performed 
from 0 to 100% IM NaCl with the running buffer 20 mM 
1-methylpiperazine buffer pH 5.0 at 4° C. 1 mL fractions 15 
were collected over the course of the run and the most active 
fraction was dialyzed versus 45% anm10nium sulfate+50 
mM potassium phosphate buffer pH 6.2+1 mM EDTA+5 
mM DTT. After four hours the sample was transferred to a 
second freshly prepared 1.5 liters of 45% anmionium sulfate 20 
solution. Following an additional 4 hours of dialysis the 
sample was centrifuged at 18,000 rpm for 15 minutes at 4° 
C. 
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well fluorescence plate (costar, black, pp). Five replicates 
were made per sample and standard curve point. 50 µl of the 
Amplex Red reagent was added to each well and incubated 
for 30 minutes at 30° C. Fluorescence readings were per-
formed in a BMG FLUOstar Galaxy micro plate reader with 
544ex/590em filter settings. 
0.6 µM resorufin above background was detected (and 
thus an equal concentration of H2 0 2 formed) upon conver-
sion of 300 µM NADH with SFNOX (0.2% yield) but could 
not detect any resorufin above background in our experiment 
with BNOX. The value found for SFNOX was above the 
detection limit of 0.25 µM [ 60] so it might indicate leakage 
of H2 0 2 which is formed during the operation of NADH 
oxidase. Nevertheless, any H2 0 2 formed only constitutes a 
very minor component of the product flux of SFNOX, 
showing that water indeed is the co-product formed during 
the NADH oxidase reaction of SFNOX and BNOX. 
Example 12 
Kinetics of Cofactor Substrates 
The kinetic analysis was performed on anmionium sulfate 
fractions from both the sfnox and bnox strains in 50 mM 
Example 11 
Hydrogen Peroxide Assay 
A novel use of an assay for H2 0 2 , based on fluorescence 
25 HEPES buffer pH 7 .0 at 30° C. The initial enzyme fractions 
were diluted in 25 mM HEPES pH 7.0 at 30° C.+25% 
glycerol+5 mM DTT to approximately -0.05 A340 nm/min 
and retained on ice during analysis. Conversion of NAD 
(P)H was followed by change of absorbance at 340 nm in a 
30 Jasco V-530 spectrophotometer. 3 mL methylacrylate dis-
posable cuvettes were used for all experiments and all runs 
were performed in triplicate at 30° C. Reactions with NADH 
were started by adding 3 µL of enzyme preparation, 9 µL for 
NADPH, to the cuvette and mixing by inversion with 
of resorufin rather than on UV-VIS spectroscopy of ABTS 
(2,2'-azino-bis[3-ethylbenzthiazoline-6-sulfonic acid])or 
o-dianisidine, has been employed successfully to demon-
strate that both NADH oxidases of the present invention 
form H20 instead ofH2 0 2 as co-product. With its detection 
limit of 100 nM, the test based on 9-acetyl-resorufin ("Am-
plex Red") is much more sensitive than the other assays 
mentioned. Horseradish peroxidase (HRP)-catalyzed oxida-
tion of 9-acetyl resorufin ("Amplex Red") to fluorescent 
resorufin was the assay. Amplex Red reacts with H2 0 2 
according to a strict 1: 1 stoichiometry. The resorufin assay 40 
("-max: 587 nm (emission), E=54,000 L(mol-cmt 1 ) with its 
extremely low detection limit of 100 nM resorufin product 
35 parafilm three times. Varying concentrations of NAD(P)H 
substrate were made my preparing 100 mL of a 300 µM 
solution in a volumetric flask. Dilutions of this solution were 
then made to provide the differing substrate concentrations 
is much more sensitive than other assays, such as ABTS or 
o-dianisidine. [ 60-62]. 
for the kinetic profile. 
Regarding the kinetics SFNOX, it was found that both 
NADH and NADPH bind rather tightly, as judged by the low 
KM value of 6.7 µM. Surprisingly, however, NADPH turned 
out to be almost as good a substrate as NADH: its v max of 11 
U/mg (at pH 7.0) is about a quarter of the value for NADH 
For the sensitive assay of putative hydrogen peroxide 
formation during the reaction of NADH oxidase the horse-
radish peroxidase-catalyzed oxidation of 9-acetyl resorufin 
was employed. The Amplex Red hydrogen peroxide assay 
45 with 39.3 U/mg. SFNOX is much more active in comparison 
with BNOX: at comparable degree of purity, the latter only 
has a v max of 2.03 U/mg, and furthermore does not accept 
NADPH as a substrate. 
kit (A-22188) from molecular probes was utilized for these 
assays. Following the protocols outlined in the kit instruc- 50 
tions, a standard curve ofH2 0 2 was prepared in the reaction 
buffer (50 mM sodium phosphate buffer pH 7.4) from the 
peroxide stock. The prepared concentrations were 20, 10, 5, 
and 2.5 µM H20 2 and 0 as a control. A working solution of 
100 µM Amplex Red reagent and 0.2 U/ml horseradish 55 
peroxidase (HRP) was prepared in the reaction buffer as per 
kit instructions. As NADH and other reducing reagents are 
known to interfere with the amplex red assay, the NADH 
oxidase enzymes were allowed to react with the substrate 
immediately prior to the Amplex Red analysis. Reaction 60 
buffer from the kit was utilized in running enzyme test with 
300 µM NADH as well as the controls without NADH. The 
enzyme conversions were performed by adding 3 µl of 
enzyme prep to 3 ml of reaction buffer with 300 µM NADH, 
mixing, and following the conversion until completion by 65 
absorbance at 340 nm. 50 µl of the final reaction mixture and 
standard curve solutions were added to each well in a 96 
Investigation of kinetic parameters with NADH and 
NADPH cofactors as substrates was performed with the 
supernatant of the 45% anmionium sulfate cut ( 40% for 
BNOXK6) in air-saturated solution at 30° C. and pH 7 .0 in 
0.1 M HEPES buffer. FIG. 3A-C demonstrates that not only 
does the SFNOX accept NADPH as a substrate with good 
reactivity (v max =ll U/mg), about 30% of activity towards 
NADH (v max =39.3 U/mg), but nearly identical KM values of 
6.7 and 6.1 µM indicate similar binding affinity. In contrast, 
BNOX only accepts NADH and at a higher KM value of 22.0 
µM than SFNOX. Chi values and error bars reveal high 
accuracy with <10% error in most cases. FIG. 3A-C shows 
the kinetics of SFNOX and BNOX with NAD(P)H cofactor 
in air-saturated solution at pH 7 and 30° C. 
The activity profile as a function of pH showed a surpris-
ing feature: instead of a bell-shaped curve a bimodal curve 
with a minimum around pH 5.5 was found. As this pH value 
is very close to the calculated pl value of pH 5.4, it is 
believed that the enzyme is not active and/or not stable at its 
US 7,163,815 B2 
39 
pl value. As a pH optimum in the acidic range is not very 
common, the superposition of pH optimum and pl does not 
happen frequently. 
With the supernatant of the 45% ammonium sulfate cut, 
an activity-pH profile was measured for SFNOX (FIG. 4). 5 
The pH optimum of activity was found at pH 5.2. Below pH 
5, activity decreased markedly and reached zero at pH 4.5. 
Rates at pH 4.5 to 5.2 are reported as net rates, with the 
chemical decomposition rate at low pH subtracted. At pH 
values above 5.2, activity falls off sharply before recovering 10 
significantly at pH 6.0, reaching a peak at pH 7.0, and then 
gradually leveling off up to pH 8.5. The sharp activity 
decline between pH 5.2 and 6.0 coincides with the enzyme's 
pl, calculated to be pH 5.4. At pH 5.5, samples instanta-




over 200 were pooled and dialyzed at 4 ° C. against 2 L of 
45% Ammonium sulfate+50 mM potassium phosphate 
buffer pH 6.8+1 mM EDTA+lO mM ~-mercaptoethanol 
using Specto/Por® regenerated cellulose dialysis membrane 
tubing (14 kD MWCO). The total dialysis time was 12 hours 
with one buffer exchange after 6 hours. The resulting 
concentrated preparation of 23 mL total volume and 1.3 
mg/mL was stored at 4 ° C. No additional purification or loss 
of activity was apparent in the 45% ammonium sulfate 
preparation. The preparation was measured to have an 
activity of 137 U/mL or 221 U/mg protein on NADH on the 
day the coupled experiments were started. 
Samples of the purified enzyme preparations were run on 
a 12% Tris-Glycine SDS-PAGE gel (PAGEr® gold precast 
gel). The running buffer and sample were prepared accord-
ing to the manufacturers protocol. The NADH oxidase 
sample was diluted 1: 10 in DI water prior to mixing with 
sample loading buffer. 20 µL of the wildtype ADH, G37D 
Activity-pH Profile of sfnoxK2 
The pH profile was performed on ammonium sulfate 
fractions from the sfnoxK2. 100 mM buffer solutions at 30° 
C. and 200 µM NADH were used for activity analysis as 
monitored by absorbance at 340 nm. All samples were tested 
in triplicate in 3 mL methylacrylate disposable cuvettes. The 
following buffers were utilized within the buffering range of 
1 pH unit from theirpKa: acetate, N-methylpiperazine, MES 
(2-[N-morpholino ]ethanesulfonic acid hydrate), and bis-tris-
propane. Sodium hydroxide or hydrochloric acid were used 
in preparation of the respective buffers. 
20 ADH mutant, and NADH oxidase (di!) samples were mixed 
with an equal volume of 2x sample loading buffer, vortexed, 
and then incubated in a water bath at 95° C. for fifteen 
minutes. Due to the presence of 50% glycerol in the purified 
wildtype ADH and G37D ADH mutant samples, sample-
25 loading buffer without glycerol was utilized. Samples were 
then centrifuged at 14,000 g for 5 minutes and placed on ice 
prior to loading on the gel. 15 to 30 µL of each sample was 
loaded into the wells with blank sample buffer added to the 
Example 14 
30 
empty wells. The gel was run on a Hoefer Mighty Small™ 
(SE260) with circulated cooling water at 4° C. The gel was 
run under constant voltage (125V) for 2.5 hours. At the 
completion of the electrophoresis run, the gel was washed 
with three changes of DI water. The gel was then stained 
Purification of NADH Oxidase 35 with Pierce Gelcode blue for 1 hour and then transferred to 
A modified purification strategy was employed to obtain 
highly purified NADH oxidase. Frozen cell pellets, 13 g 
WCP, were thawed and resuspended in 30 mL of 100 mM 
1-methylpiperazine buffer pH 5.0+1 mM EDTA+5 mM 
DTT+5 mM Spermine. The resulting cell slurry was soni- 40 
cated with a Fisher Scientific 60 Sonic dismembrator for 6x2 
minutes while floating the tube in ice/water for cooling. The 
resulting lysate was centrifuged at 20,000 rpm in a Beckman 
J2-21M for 45 minutes at 4° C. The clarified lysate was then 
loaded into Specto/Por® regenerated cellulose dialysis 45 
membrane tubing (60 K MWCO) and dialyzed with 1.5 L of 
20 mM 1-methylpiperazine pH 5.0 at 30° C.+1 mM EDTA+ 
DI water to destain for an additional hour. Images were 
taken in an Alpha Innotech Alphalmager 3300 for gel 
documentation. 
Example 15 
Cofactor Regenerating Assay: 
Application ofNADH oxidase in cofactor regeneration is 
performed using a batch conversion with R-ADH as the 
production enzyme. All reactions were run at 30° C. with 
standard buffer composed: 50 mM HEPES pH 7.0 at 30° C. 
and 150 mM total ionic strength by addition of 138 mM 
NaCl, 5 mM DTT, 1 mM MgCl2 , and 100 mM racemic 
phenylethanol. Cofactors and enzymes were then added to 
100 µL of buffer as outlined in Table 3 and vortexed. 30 µL 
of the mixed solution was then added to 0.65 mL polypro-
pylene PCR reaction tubes, capped, and floated in a water 
bath. Three identical vials were prepared for each condition. 
Time point samples were taken by centrifuging for 1 min at 
14,000 rpm in a Microfuge and adding 270 µL methanol to 
the reaction vial. 
10 mM ~-mercaptoethanol. This step comprises the acid 
precipitation step along with concurrent dialysis for salt 
removal. The sample was dialyzed versus 1.5 L of buffer for 50 
two hours at 30 C and 200 rpm stirring before exchanging 
the dialysis buffer and dialyzing for two more hours under 
the same conditions. Temperature and stirring conditions 
were maintained by a digital stir plate with and external 
temperature probe. The sample was then transferred and 55 
centrifuged at 20,000 rpm for 45 minutes at 4° C. The 
resulting clarified solution was then loaded onto a Amer-
sham Pharmacia Hiprep 16/10 Source™ 30Q column on an 
AKTAexplorer system at 4° C. The protein was then eluted 
with displacement chromatography utilizing 5 mM naphtha-
lene-1,3,6-trisulfonic acid. After sample loading the column 
was washed with 10 column volumes of 20 mM 1-meth-
ylpiperazine pH 5.0 at 4° C.+5 mM DTT. The protein elution 
phase was then started by switching to 20 mM 1-methylpip-
erazine pH 5.0 at 4° C.+5 mM DTT+5 mM naphthalene-I, 
3,6-trisulfonic acid. 5 mL factions were collected at a flow 
rate of 5 ml/min. Fractions with a tested specific activity of 
The results of coupled reactions after 12 hours, as ana-
60 lyzed by selective ion monitoring (SIM) mass spectrometry, 
are shown in Table 4. The standard curves used for SIM 
mass spectrometry are shown in FIG. 5. Measured degrees 
of conversion values were normalized using the mass bal-
ance of acetophenone and phenylethanol to correct for 
65 manual injection error. Satisfactory linearity was obtained 
for both phenyl ethanol and acetophenone up to 100 mM 
concentration. 
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TABLE 4 
Cou12led alcohol-ketone conversion with cofactor regeneration 
ADH NADH Normalized 
Sam- Cofactor ADH mut ox Conversion 
ple# (4mM) (U/ml) (U/ml) (U/ml) (%) 
NAD 2.0 8.0 43.6 
2 NADH 2.0 8.0 35.0 
NADP 2.0 8.0 38.2 
4 NADPH 2.0 8.0 40.1 
NAD 8.0 -2.3 
NAD 2.0 1.7 
7 NADP 8.0 -0.7 












from the scope or spirit of the invention. Other embodiments 
of the invention will be apparent to those skilled in the art 
from consideration of the specification and practice of the 
invention disclosed herein. It is intended that the specifica-
tion and examples be considered as exemplary only, with a 
true scope and spirit of the invention being indicated by the 
following claims. 
REFERENCES 
[1] A. Zaks, "Industrial biocatalysis", Curr. Opin. Chem. 
Biol. 2001, 5, 130-136 
[2] A. Liese and M. V. Filho, "Production of fine chemicals 
using biocatalysis", Curr. Opin. Biotechnol. 1999, 10, 
9 NAD* 2.0 8.0 43.6 109.0 
10 NADP* 2.0 8.0 40.2 100.5 
15 595-603 
11 NAD* 2.0 4.0 27.9 69.8 
12 NADP* 2.0 4.0 41.7 104.1 
*These samples utilized 0.4 mM concentrations of cofactor. 
20 
Standard Conditions: 
30° C., pH 7.0 (50 mM HEPES), 5 mM DTT, 1 mM MgC12 , 
150 mM total ionic strength (addition of 138 mM NaCl), and 
100 mM racemic phenylethanol. 
The coupled reaction results shown in Table 4 are con- 25 
sistent with expected results from successfully coupled 
reactions. The comparison of reduced versus oxidized cofac-
tor (runs 1 & 2 a well as 3 & 4) indicate that the starting 
oxidation state of the cofactor does not significantly impact 
the results. Given the higher stability and lower cost, the 30 
oxidized cofactor would be the reagent of choice for typical 
coupled reactions. The controls (runs 5-8) demonstrated that 
no conversion occurs without ADH (runs 5 & 7) and that 
slightly less than stoichiometric conversion was observed in 
the absence ofNADH oxidase (runs 6 & 8) to regenerate the 35 
cofactor. Conversions in excess of stoichiometry would have 
indicated a potential NAD(P)H-oxidizing impurity in the 
ADH preparations. Reducing the cofactor concentration to 
0.4 mM (runs 9-12) still indicated effective conversion with 
concomitant higher number of turnovers of cofactor; how- 40 
ever, a lower degree of conversion was observed for the 
mutant ADH in the presence of 4 U/mL instead of 8 U/mL 
NADH oxidase. After 12 h, nearly complete conversion 
(maximally 50% of racemic phenyl ethanol) was achieved in 
all but the case of the mutant ADH with NAD+. 45 
Example 16 
GC/MS Analysis 50 
Samples and a prepared standard curve were submitted to 
the IBB central mass spectroscopy facility for QC/selective 
ion analysis. The separate standard curves were prepared for 
the ±phenylethanol and acetophenone. The ±phenylethanol 
curve consisted of 100 mM, 10 mM, and 1 mM in the 55 
coupled reaction base buffer, diluted 1: 10 in methanol. The 
acetophenone curve consisted of 50 mM, 10 mM, and 1 mM 
in the coupled reaction base buffer, diluted 1: 10 in methanol. 
Total mass areas were reported for ions of mass 120 (ac-
etophenone) and 122 (±phenylethanol). Sample concentra- 60 
tions from the coupled reaction were estimated by interpo-
lation on these standard curves (R2 for both curves>0.90). 
Whereas this invention has been described in detail with 
particular reference to its most preferred embodiments, it 
will be apparent to those skilled in the art that various 65 
modifications and variations can be made in the present 
invention in light of the above teachings without departing 
[3] J. D. Rozzell, "Biocatalysis at commercial scale: Myths 
and realities", Chimica Oggi 1999, 42-47 
[4] A. S. Bommarius, M. Schwarm and K. Drauz, "Com-
parison of Different Chemoenzymatic Process Routes to 
Enantiomerically Pure Amino Acids", Chimia 2001, 55, 
50-59 
[5] D. A. Evans, T. C. Britton, J. A. Ellman and R. L. Dorow, 
1990, "The asymmetric synthesis of a-amino acids. Elec-
trophilic azidation of chiral imide enolates, a practical 
approach to the synthesis of (R)- and (S)-a-azido car-
boxylic acids", J. Am. Chem. Soc., 112, 4011-4030 
[6] U. Groth, C. Schmeck and U. Schiillkopf, 1993, "Asym-
metric synthesis of a-amino acid benzyl esters via the 
bisbenzyl bislactim ether of cyclo(-L-Val-Gly-)", Liebigs 
Ann. Chem., 321-323 
[7] W. Hummel, 1997, "New alcohol dehydrogenases forthe 
synthesis of chiral compounds", Adv. Biochem. Eng. 
Biotechnol., 58, 145-84 
[8] M. J. Kim and G. M. Whitesides, 1988, "L-Lactate 
dehydrogenase: substrate specificity and use as a catalyst 
in the synthesis of homochiral 2-hydroxy acids", J. Am. 
Chem. Soc., 110, 2959-64 
[9] H.K. W. Kallwass, 1992, "Potential of R-2-hydroxyiso-
caproate dehydrogenase from Lactobacillus casei for ste-
reospecific reductions", Enzyme Microb. Technol., 14, 
28-35 
[10] G. Krix, A. S. Bommarius, K. Drauz, M. Kottenhahn, 
M. Schwarm and M.-R. Kula, 1997, "Enzymatic reduc-
tion of a-keto acids leading to L-amino acids or D-hy-
droxy Acids", J. Biotechnology, 53, 29-39 
[11] Y. Asano, A. Yamada, Y. Kato, K. Yamaguchi, Y. 
Hibino, K. Hirai and K. Kondo, 1990, "Enantioselective 
synthesis of (S)-amino acids by phenylalanine dehydro-
genase from Bacillus sphaericus: Use of natural and 
recombinant enzymes", J. Org. Chem., 55, 5567-5571 
[12] C. W. Bradshaw, C.H. Wong, W. Hummel and M.-R. 
Kula, 1991, "Enzyme-catalyzed asymmetric synthesis of 
(S)-2-amino-4-phenylbutanoic acid and (R)-2-hydroxy-4-
phenylbutanoic acid", Biorg. Chem., 19, 29-39 
[13] R. L. Hanson, J. M. Howell, T. L. LaPorte, M. J. 
Donovan, D. L. Cazzulino, V. V. Zannella, M.A. Mon-
tana, V. B. Nanduri, S. R. Schwarz, R. F. Eiring, S. C. 
Durand, J. M. Wasylyk, W. L. Parker, M.S. Liu, F. J. 
Okuniewicz, B. Chen, J. C. Harris, K. J. Natalie, K. 
Ramig, S. Swaminathan, V. W. Rosso, S. K. Pack, B. T. 
Lotz, P. J. Bernot, A. Rusowicz, D. A. Lust, K. S. Tse, J. 
J. Venit, L. J. Szarka, and R. N. Patel, 2000, "Synthesis of 
US 7,163,815 B2 
43 
allysine ethylene acetal using phenylalanine dehydroge-
nase from Thermoactinomyces intermedius", Enzyme 
Microb Technol, 26, 348-358 
[14] R. L. Hanson, M. D. S.,A. Banerjee, D. B. Brzozowski, 
B.-C. Chen, B. P. Patel, C. G. McNamee, G. A. Kodersha, 
D.R. Kronenthal, R. N. Patel and L. J. Szarka, Bioorganic 
& Medicinal Chemistry 1999, 7, 2247-2252 
[15] A. Willetts, 1997, "Structural studies and synthetic 
applications ofBaeyer-Villiger monooxygenases", Trends 10 
Biotechnol., 15, 55-62 
[16] M.-R. Kula, 1994, "Enzyme catalyzed reductions of 
carbonyl groups", Chiral Europe, Nice, France, Spring 
Innovations, Ltd., Stockport UK 
[17] H. K. Chenault, G. M. Whitesides, Appl. Biochem. 15 
Biotechnol. 1987, 14, 147-97 
[18] C. Wandrey, in: Proceedings of the 4th European 
Congress on Biotechnology (eds.: 0. M. Neijssel, R.R. 
van der Meer, and K. Ch. A. M. Luyben), Amsterdam, 20 
1987, vol. 4, 171-188 
[19] E. Keinan, K.K. Seth, R. J. Lamed, Ann. NY Acad. 
Sciences (Enzyme Engineering 8) 1987, 501, 130-150 
[20] W. Hummel, M.-R. Kula, Eur. J. Biochem, 1989, 184, 
1-13 25 
[21] R. Wichmann, C. Wandrey, A. F. Bueckmann, M.-R. 
Kula, J. Biotechnol, 1981, 23, 2789-2802 
[22] U. Krag!, D. Vasic-Racki, C. Wandrey, Chem. Ing. 
Tech, 1992, 64, 499-509 
[23] A. S. Bommarius, Habilitation thesis, RWTH Aachen, 
Aachen, Germany, 2000 
[24] V. I. Tishkov, A. G. Galkin, V. V. Fedorchuk, P. A. 
Savitsky, A. M. Rojkova, H. Gieren, M.-R. Kula, Bio-
30 
technol. Bioeng. 1999, 64, 187-93 35 
[25] K. Seelbach, B. Riebel, W. Hummel, M.-R. Kula, V. I. 
Tishkov, A. M. Egorov, C. Wandrey, U. Krag!, Tetrahe-
dron Letters 1996, 37, 1377-80 
[26] C.-H. Wong, G. M. Whitesides, J. Amer. Chem. Soc. 
40 
1981, 103, 4890-4899 
[27] C.-H. Wong, D. G. Drueckhammer, Bio/technology 
1985, 3, 649-651 
[28] D. G. Drueckhammer, PhD Thesis, Texas A and M 
Univ., College Station/TX, USA, 1987 45 
[29] M. Kataoka, L. P. Rohani, K. Yamamoto, M. Wada, H. 
Kawabata, K. Kita, H. Yanase, S. Shimizu, Appl. Micro-
bial. Biotechnol. 1997, 48, 699-703 
[30] R. P. Ross, A. Claiborne, J. Mo!. Biol. 1992, 227, 
658-71 50 
[31] J. Matsumoto, M. Higushi, M. Shimada, Y. Yamamoto, 
Y. Kamio, Biosci. Biotechnol. Biochem. 1996, 60, 39-43 
[32] D. E. Ward, C. J. Donnelly, M. E. Mullendore, J. van 
der Oost, W. M. de Vos, and E. J. Crane 3rd, Eur. J. 55 
Biochem. 2001, 268, 5816-23 
[33] Y. Yamamoto, Y. Kamio, Tanpakushitsu Kakusan Koso 
2001, 46, 726-32 
[34] B. R. Riebel, P. R. Gibbs, W. B. Wellborn, A. S. 
Bommarius, Adv. Synth. Cat. 2002, 344, 1156-1169 
[35] W. Hummel and M.-R. Kula, 1989, "Dehydrogenases 
for the synthesis of chiral compounds", Eur. J. Biochem., 
184, 1-13 
60 
[36] T. Ohshima and K. Soda, 1990, "Biochemistry and 65 
biotechnology of amino acid dehydrogenases", Adv. Bio-
chem. Eng./Biotech., 42, 187-209 
44 
[37] W. Hurnniel, "Large-scale applications of NAD(P)-
dependent oxidoreductases: recent developments", 
TIBTECH 1999, 17, 487-492 
[38] R. Wichmann, C. Wandrey, A. F. B"ickmann and M.-R. 
Kula, 1981, "Continuous enzymatic transformation in an 
enzyme membrane reactor with simultaneous NADH 
regeneration", Biotechnol. Bioeng., 23, 2789-2802 
[39] M.-R. Kula and C. Wandrey, 1987, "Continuous enzy-
matic transformation in an enzyme-membrane-reactor 
with simultaneous NADH regeneration", Meth. Enzymol. 
136, 9-21 
[40] G. L. Lemiere, J. A. Lepoivre and F. C. Alderweireldt, 
1985, "HLAD-catalyzed oxidations of alcohols with 
acetaldehyde as a coenzyme recycling substrate", Tetra-
hedron Lett., 26, 4527-28 
[41] a) M. D. Bednarski, H.K. Chenault, E. S. Simon and 
G. M. Whitesides, 1987, "Membrane-enclosed enzymic 
catalysis (MEEC): a useful, practical new method for the 
manipulation of enzymes in organic synthesis", J. Amer. 
Chem. Soc., 109, 1283-85; b) H.K. Chenault and G. M. 
Whitesides, 1989, "Lactate dehydrogenase-catalyzed 
regeneration of NAD from NADH for use in enzyme-
catalyzed synthesis", Bioorg. Chem., 17, 400-9 
[42] G. Carrea, R. Bovara, R. Longhi and S. Riva, 1985, 
"Preparation of 12-ketochenodeoxycholic acid from 
cholic acid using coimmobilized 12a-hydroxysteroid 
dehydrogenase and glutamate dehydrogenase with 
NADP+ cycling at high efficiency", Enz. Microb. Tech-
nol., 7, 597-600 
[43] L. G. Lee and G. M. Whitesides, 1985, "Enzyme-
catalyzed organic synthesis: a comparison of strategies for 
in situ regeneration ofNAD from NADH", J. Am. Chem. 
Soc., 107, 6999-7008 
[44] H.J. Park, C. 0. Reiser, S. Kondruweit, H. Erdmann, 
R. D. Schmid and M. Sprinzl, 1992, "Purification and 
characterization of a NADH oxidase from the thermophile 
Thermus thermophilus HB8", Eur. J. Biochem., 205, 
881-5 
[45] R. E. Altomare, J. Kohler, P. F. Greenfield and J. R. 
Kittrell, 1974, "Deactivation of immobilized beef liver 
catalase by hydrogen peroxide", Biotechnol. Bioeng., 16, 
1659-73 
[56] K. Koike, T. Kobayashi, S. Ito and M. Saitoh, 1985, 
"Purification and characterization of NADH Oxidase 
from a strain of Leuconostoc meserentoides", J. Bio-
chem., 97, 1279-1288 
[47] R. P. Ross and A. Claiborne, 1991, "Cloning, sequence 
and overexpression of NADH peroxidase from Strepto-
coccus faecalis 1 OCI. Structural relationship with the 
flavoprotein disulfide reductases", J. Mo!. Biol., 221, 
857-871 
[48] R. P. Ross and A. Claiborne, 1992, "Molecular Cloning 
and Analysis of the Gene Encoding the NADH-Oxidase 
from Streptococcus faecalis lOCI. Comparison with 
NADH-Peroxidase and the Flavoprotein Disulfide Reduc-
tases", J. Mo!. Biol., 227, 658-671 
[49] S. N. Peterson, P. C. Hu, K. F. Bott and C. A. 
Hutchinson 3rd, 1993, "A survey of the Mycoplasma 
genitalium genome by using random sequencing", J. 
Bacterial., 175, 7918-7930 
US 7,163,815 B2 
45 46 
[50] J. Matsumoto, M. Higushi, M. Shimada, Y. Yamamoto 
and Y. Kamio, 1996, "Molecular cloning and sequence 
analysis of the gene encoding the H2 0-Forming NADH 
Oxidase from Streptococcus mutans", Biosci. Biotech. 
Biochem., 60, 39-43 
[60] S. Lindsay, D. Brosnahan and G. D. Watt, 2001, 
"Hydrogen peroxide formation during iron deposition in 
horse spleen ferritin using 0 2 as an oxidant", Biochem-
istry, 40, 3340--7 
[51] C. J. Bult, 0. White, G. J. Olsen, L. Zhou, R. D. 
[61] M. Zhou, Z. Diwu, N. Panchuk-Voloshina, R. P. 
Fleischmann, G. G. Sutton, J. A. Blake, L. M. FitzGerald, 
R. A. Clayton, J. D. Gocayne, A. R. Kerlavage, B. A. 
Dougherty, J. F. Tomb, M. D. Adams, C. I. Reich, R. 10 
Overbeek, E. F. Kirkness, K. G. Weinstock, J.M. Merrick, 
Haugland, 1997, "A stable nonfluorescent derivative of 
resorufin for the fluorometric determination of trace 
hydrogen peroxide: applications in detecting the activity 
of phagocyte NADPH oxidase and other oxidases", Anal. 
Biochem., 253, 162-168 A. Glodek, J. L. Scott, N. S. Geoghagen, J. C. Venter, 
1996, "Complete genome sequence of the methanogenic 
archaeon, Methanococcus jannaschii", Science, 273, 
1058-1073 
[62] J. G. Mohanty, J. S. Jaffe, E. S. Schulman and D. G. 
[52] V. Natarajan, S. M. Cramer, J. Chromatography A2000, 
876, 63-73 
15 
Raible, 1997, "A highly sensitive fluorescent micro-assay 
of H20 2 release from activated human leukocytes using a 
dihydroxyphenoxazine derivative", J. Immunol. Methods, 
202, 133-141 [53] A. Kundu, S. Vunnum, S. M. Cramer, J. Chromatog-
raphy A 1995, 707, 57-67 20 [63] R. K. Scopes, Protein purification: principles and 
practice, Springer, New York, 3rd edition, 1994 [54] W. Hummel, Adv. Biochem. Eng. 1997, 58, 145-184 
[55] B. Riebel, W. Hummel, A. Bommarius, Eur. Pat. Appl. [64] B. R. Riebel, P. R. Gibbs, W. B. Wellborn and A. S. 
EP 1,176,203, 2002 
[56] W. Hummel, Trends Biotechnol, 1999, 17, 487-92 
[57] B. Riebel, PhD thesis, University of Dusseldorf, Dus- 25 
seldorf, Germany, 1997 
Bommarius, "Cofactor regeneration of NAD+ from 
NADH: novel water-forming NADH oxidases", Adv. 
Synth. Cata!. 2002, 344, 1156-1168. 
[58] M. Walberg, W. Hummel, M. Mueller, Chemistry 2001, 
7, 4562-71 
[65] B. R. Riebel, P. R. Gibbs, W. B. Wellborn and A. S. 
[59] J. Haberland, A. Kriegesmann, E. Wolfram, W. Hum-
30 
me!, A. Liese, Appl. Microbial Biotechnol, 2002, 58, 
595-9 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 20 
<210> SEQ ID NO 1 
<211> LENGTH: 1359 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<220> FEATURE: 
<221> NAME/KEY: CDS 
<222> LOCATION: (1) .. (1359) 
<400> SEQUENCE: 1 
atg aaa gtt att gta gta ggt tgt act cac get ggc act ttt 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe 
1 5 10 
aag caa acg att gee gat cac CCC gat gca gat gtg act gca 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Ala 
20 25 30 
atg aat gat aac att tee ttt tta tea tgt gga ate gee ctt 
Met Asn Asp Asn Ile Ser Phe Leu Ser Cys Gly Ile Ala Leu 
35 40 45 
ggt aaa gaa att aaa aac aat gat CCC cga ggg ctt ttc tac 
Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr 
50 55 60 
cca gaa gaa tta age aat ctt gga get aac gtc caa atg cgt 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg 
65 70 75 
Bommarius, Cofactor regeneration of both NAD+ from 
NADH and NADP+ from NADPH: NADH oxides from 
Lactobacillus sanfranciscensis ",Adv. Synth. Cata!. 2003, 
345, 707-712. 
gca gtt 48 
Ala Val 
15 
tat gaa 96 
Tyr Glu 
tac tta 144 
Tyr Leu 
tea agt 192 
Ser Ser 
cat caa 240 
His Gln 
80 
gtt aca aac gtt gat cca gaa aca aaa aca ate aaa gtt aaa gat tta 288 
US 7,163,815 B2 
47 48 
-continued 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
ate ace aac gaa gaa aaa aca gaa gca tat gac aaa tta att atg ace 336 
Ile Thr Asn Glu Glu Lys Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
act ggt tct aag cct act gtt cct cca ate cct gga ate gat agt agt 384 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
cgc gtt tac ctt tgt aaa aac tat aac gat get aaa aag tta ttt gaa 432 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
gaa get ccc aaa get aaa acg att act ate att ggt tct ggt tat att 480 
Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
ggt gee gaa ctg get gaa gee tac tea aac caa aat tat aac gtt aat 528 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
tta att gat ggt cat gaa cga gtt ctt tac aag tat ttt gat aaa gaa 576 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
ttt act gat att tta gee aaa gat tat gaa get cat ggt gtt aac ctg 624 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
gtt ctt ggt tea aaa gta get get ttt gaa gaa gtc gat gat gaa att 672 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
ate act aaa ace eta gat ggt aaa gaa att aaa tct gat att gca att 720 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
ctt tgt ate ggt ttc cgc cct aac act gaa tta ctt aaa ggt aaa gtt 768 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Glu Leu Leu Lys Gly Lys Val 
245 250 255 
gee atg ttg gat aac ggt gca ate att act gat gaa tac atg cat tea 816 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
tea aat cgc gac att ttt get get ggt gat agt gee gee gtt cac tac 864 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
aac ccc act aat tct aac gee tac att cct tta get ace aac gee gta 912 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
cgc caa ggg aga tta gtt ggc eta aat ctg act gaa gac aaa gta aaa 960 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
gac atg gga ace caa tct tea tct ggt ctt aaa eta tac ggt egg act 1008 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
tat gtc tea act gga ate aat acg get ctt get aaa gee aat aat tta 1056 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
340 345 350 
aaa gtt age gaa gta ate ata get gat aat tat cgt cca gaa ttt atg 1104 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
tta tea acg gat gaa gtt tta atg tea tta gtg tat gat cct aag act 1152 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
cgt gta att ttg gga ggg gcg ctt tea agt atg cac gat gtt tcg caa 1200 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
US 7,163,815 B2 
49 
-continued 
tea gcg aac gtc tta tea gta tgt att caa aat aaa aac acg att gac 1248 
Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
gat tta gca atg gtg gat atg tta ttc caa cca caa ttt gat cgt ccg 1296 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
ttt aac tac tta aac att eta ggc caa get get caa gca caa get gac 1344 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
aaa gca cat aaa taa 1359 
Lys Ala His Lys 
450 
<210> SEQ ID NO 2 
<211> LENGTH: 452 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 2 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe Ala Val 
1 5 10 15 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Ala Tyr Glu 
20 25 30 
Met Asn Asp Asn Ile Ser Phe Leu Ser Cys Gly Ile Ala Leu Tyr Leu 
35 40 45 
Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr Ser Ser 
50 55 60 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg His Gln 
65 70 75 80 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
Ile Thr Asn Glu Glu Lys Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Glu Leu Leu Lys Gly Lys Val 
245 250 255 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
50 
US 7,163,815 B2 
51 
-continued 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
340 345 350 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
Lys Ala His Lys 
450 
<210> SEQ ID NO 3 
<211> LENGTH: 1359 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<220> FEATURE: 
<221> NAME/KEY: CDS 
<222> LOCATION: (1) .. (1359) 
<400> SEQUENCE: 
atg aaa gtt att gta gta ggt tgt act cac get ggc act ttt gca gtt 48 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe Ala Val 
1 5 10 15 
aag caa acg att gee gat cac ccc gat gca gat gtg act gta tat gaa 96 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Val Tyr Glu 
20 25 30 
atg aat gat aac att tee ttt tta tea tgt gga ate gee ctt tac tta 144 
Met Asn Asp Asn Ile Ser Phe Leu Ser Cys Gly Ile Ala Leu Tyr Leu 
35 40 45 
ggt aaa gaa att aaa aac aat gat ccc cga ggg ctt ttc tac tea agt 192 
Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr Ser Ser 
50 55 60 
cca gaa gaa tta age aat ctt gga get aac gtc caa atg cgt cat caa 240 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg His Gln 
65 70 75 80 
gtt aca aac gtt gat cca gaa aca aaa aca ate aaa gtt aaa gat tta 288 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
ate ace aac gaa gaa aaa aca gaa gca tat gac aaa tta att atg ace 336 
Ile Thr Asn Glu Glu Lys Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
act ggc tct aag cct act gtt cct cca ate cct gga ate gat agt agt 384 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
52 
US 7,163,815 B2 
53 54 
-continued 
cgc gtt tac ctt tgt aaa aac tat aac gat get aaa aag tta ttt gaa 432 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
gaa get ccc aaa get aaa acg att act ate att ggt tee ggt tat att 480 
Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
ggt gee gaa ctg get gaa gee tac tea aac caa aat tat aac gtt aat 528 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
tta att gat ggt cat gaa cga gtt ctt tac aag tat ttt gat aaa gaa 576 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
ttt act gat att tta gee aaa gat tat gaa get cat ggt gtt aac ctg 624 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
gtt ctt ggt tea aaa gta get get ttt gaa gaa gtc gat gat gaa att 672 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
ate act aaa ace eta gat ggt aaa gaa att aaa tct gat att gca att 720 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
ctt tgt ate ggt ttc cgc cct aac act gaa tta ctt aaa ggt aaa gtt 768 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Glu Leu Leu Lys Gly Lys Val 
245 250 255 
gee atg ttg gat aac ggt gca ate att act gat gaa tac atg cat tea 816 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
tea aat cgc gac att ttt get get ggt gat agt gee gee gtt cac tac 864 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
aac ccc act aat tct aac gee tac att cct tta get ace aac gee gta 912 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
cgc caa ggg aga tta gtt ggc eta aat ctg act gaa gac aaa gta aaa 960 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
gac atg gga ace caa tct tea tct ggt ctt aaa eta tac ggt egg act 1008 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
tat gtc tea act gga ate aat acg get ctt get aaa gee aat aat tta 1056 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
340 345 350 
aaa gtt age gaa gta ate ata get gat aat tat cgt cca gaa ttt atg 1104 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
tta tea acg gat gaa gtt tta atg tea tta gtg tat gat cct aag act 1152 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
cgt gta att ttg gga ggg gcg ctt tea agt atg cac gat gtt tcg caa 1200 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
tea gcg aac gtc tta tea gta tgt att caa aat aaa aac acg att gac 1248 
Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
gat tta gca atg gtg gat atg tta ttc caa cca caa ttt gat cgt ccg 1296 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
ttt aac tac tta aac att eta ggc caa get get caa gca caa get gac 1344 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
US 7,163,815 B2 
55 
-continued 
aaa gca cat aaa taa 
Lys Ala His Lys 
450 
<210> SEQ ID NO 4 
<211> LENGTH: 452 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe Ala Val 
1 5 10 15 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Val Tyr Glu 
20 25 30 
Met Asn Asp Asn Ile Ser Phe Leu Ser Cys Gly Ile Ala Leu Tyr Leu 
35 40 45 
Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr Ser Ser 
50 55 60 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg His Gln 
65 70 75 80 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
Ile Thr Asn Glu Glu Lys Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Glu Leu Leu Lys Gly Lys Val 
245 250 255 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
56 
1359 
US 7,163,815 B2 
57 
-continued 
340 345 350 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
Lys Ala His Lys 
450 
<210> SEQ ID NO 5 
<211> LENGTH: 1359 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<220> FEATURE: 
<221> NAME/KEY: CDS 
<222> LOCATION: (1) .. (1359) 
<400> SEQUENCE: 5 
atg aaa gtt att gta gta ggt tgt act cac get ggc act ttt gca gtt 48 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe Ala Val 
1 5 10 15 
aag caa acg att gee gat cac ccc gat gca gat gtg act gta tat gaa 96 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Val Tyr Glu 
20 25 30 
atg aat gat aac att tee ttt tta tea tgt gga ate gee ctt tac tta 144 
Met Asn Asp Asn Ile Ser Phe Leu Ser Cys Gly Ile Ala Leu Tyr Leu 
35 40 45 
ggt aaa gaa att aaa aac aat gat ccc cga ggg ctt ttc tac tea agt 192 
Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr Ser Ser 
50 55 60 
cca gaa gaa tta age aat ctt gga get aac gtc caa atg cgt cat caa 240 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg His Gln 
65 70 75 80 
gtt aca aac gtt gat cca gaa aca aaa aca ate aaa gtt aaa gat tta 288 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
ate ace aac gaa gaa aga aca gaa gca tat gac aaa tta att atg ace 336 
Ile Thr Asn Glu Glu Arg Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
act ggt tct aag cct act gtt cct cca ate cct gga ate gat agt agt 384 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
cgc gtt tac ctt tgt aaa aac tat aac gat get aaa aag tta ttt gaa 432 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
gaa get ccc aaa get aaa acg att act ate att ggt tct ggt tat att 480 
Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
ggt gee gaa ctg get gaa gee tac tea aac caa aat tat aac gtt aat 528 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
58 
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59 
-continued 
tta att gat ggt cat gaa cga gtt ctt tac aag tat ttt gat aaa gaa 576 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
ttt act gat att tta gee aaa gat tat gaa get cat ggt gtt aac ctg 624 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
gtt ctt ggt tea aaa gta get get ttt gaa gaa gtc gat gat gaa att 672 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
ate act aaa ace eta gat ggt aaa gaa att aaa tct gat att gca att 720 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
ctt tgt ate ggt ttc cgc cct aac act gga tta ctt aaa ggt aaa gtt 768 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Gly Leu Leu Lys Gly Lys Val 
245 250 255 
gee atg ttg gat aac ggt gca ate att act gat gaa tac atg cat tea 816 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
tea aat cgc gac att ttt get get ggt gat agt gee gee gtt cac tac 864 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
aac ccc act aat tct aac gee tac att cct tta get ace aac gee gta 912 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
cgc caa ggg aga tta gtt ggc eta aat ctg act gaa gac aaa gta aaa 960 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
gac atg gga ace caa tee tea tct ggt ctt aaa eta tac ggt egg act 1008 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
tat gtc tea act gga ate aat acg get ctt get aaa gee aat aat tta 1056 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
340 345 350 
aaa gtt age gaa gta ate ata get gat aat tat cgt cca gaa ttt atg 1104 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
tta tea acg gat gaa gtt tta atg tea tta gtg tat gat cct aag act 1152 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
cgt gta att ttg gga ggg gcg ctt tea agt atg cac gat gtt tcg caa 1200 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
tea gcg aac gtc tta tea gta tgt att caa aat aaa aac acg att gac 1248 
Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
gat tta gca atg gtg gat atg tta ttc caa cca caa ttt gat cgt ccg 1296 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
ttt aac tac tta aac att eta ggc caa get get caa gca caa get gac 1344 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
aaa gca cat aaa taa 1359 
Lys Ala His Lys 
450 
<210> SEQ ID NO 6 
<211> LENGTH: 452 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
60 
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61 
-continued 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe Ala Val 
1 5 10 15 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Val Tyr Glu 
20 25 30 
Met Asn Asp Asn Ile Ser Phe Leu Ser Cys Gly Ile Ala Leu Tyr Leu 
35 40 45 
Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr Ser Ser 
50 55 60 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg His Gln 
65 70 75 80 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
Ile Thr Asn Glu Glu Arg Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Gly Leu Leu Lys Gly Lys Val 
245 250 255 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
340 345 350 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
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Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
Lys Ala His Lys 
450 
<210> SEQ ID NO 7 
<211> LENGTH: 1335 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<220> FEATURE: 
<221> NAME/KEY: CDS 
<222> LOCATION: (1) .. (1335) 
<400> SEQUENCE: 
atg atg aaa ata ata att att ggg ggc aca tea gca gga act agt gee 48 
Met Met Lys Ile Ile Ile Ile Gly Gly Thr Ser Ala Gly Thr Ser Ala 
1 5 10 15 
gca get aaa gca aac cgc tta aac aaa aag eta gac att act ate tat 96 
Ala Ala Lys Ala Asn Arg Leu Asn Lys Lys Leu Asp Ile Thr Ile Tyr 
20 25 30 
gaa aaa aca aat att gta tct ttt gga ace tgt ggc ctg cct tac ttt 144 
Glu Lys Thr Asn Ile Val Ser Phe Gly Thr Cys Gly Leu Pro Tyr Phe 
35 40 45 
gtg ggg gga ttc ttt gac aac ccc aat aca atg ate tea aga aca caa 192 
Val Gly Gly Phe Phe Asp Asn Pro Asn Thr Met Ile Ser Arg Thr Gln 
50 55 60 
gaa gaa ttc gaa aaa act gga ate tct gtt aaa act aac cac gaa gtt 240 
Glu Glu Phe Glu Lys Thr Gly Ile Ser Val Lys Thr Asn His Glu Val 
65 70 75 80 
ate aaa gta gat gca aaa aac aat aca att gta ata aaa aat caa aaa 288 
Ile Lys Val Asp Ala Lys Asn Asn Thr Ile Val Ile Lys Asn Gln Lys 
85 90 95 
aca gga ace att ttt aac aat act tac gat caa ctt atg ata gca act 336 
Thr Gly Thr Ile Phe Asn Asn Thr Tyr Asp Gln Leu Met Ile Ala Thr 
100 105 110 
ggt gca aaa cct att att cca cca ate aat aat ate aat eta gaa aat 384 
Gly Ala Lys Pro Ile Ile Pro Pro Ile Asn Asn Ile Asn Leu Glu Asn 
115 120 125 
ttt cat act ctg aaa aat tta gaa gac ggt caa aaa ata aaa aaa tta 432 
Phe His Thr Leu Lys Asn Leu Glu Asp Gly Gln Lys Ile Lys Lys Leu 
130 135 140 
atg gat aga gaa gag att aaa aat ata gtg ata att ggt ggt gga tac 480 
Met Asp Arg Glu Glu Ile Lys Asn Ile Val Ile Ile Gly Gly Gly Tyr 
145 150 155 160 
att gga att gaa atg gta gaa gca gca aaa aat aaa aga aaa aat gta 528 
Ile Gly Ile Glu Met Val Glu Ala Ala Lys Asn Lys Arg Lys Asn Val 
165 170 175 
aga tta att caa eta gat aag cac ata etc ata gat tee ttt gac gaa 576 
Arg Leu Ile Gln Leu Asp Lys His Ile Leu Ile Asp Ser Phe Asp Glu 
180 185 190 
gaa ata gtc aca ata atg gaa gaa gaa eta aca aaa aag ggg gtt aat 624 
Glu Ile Val Thr Ile Met Glu Glu Glu Leu Thr Lys Lys Gly Val Asn 
195 200 205 
ctt cat aca aat gag ttt gta aaa agt tta ata gga gaa aaa aag gca 672 
Leu His Thr Asn Glu Phe Val Lys Ser Leu Ile Gly Glu Lys Lys Ala 
64 
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65 
-continued 
210 215 220 
gaa gga gta gta aca aac aaa aat act tat caa get gac get gtt ata 720 
Glu Gly Val Val Thr Asn Lys Asn Thr Tyr Gln Ala Asp Ala Val Ile 
225 230 235 240 
ctt get ace gga ata aaa cct gac act gaa ttt tta gaa aac cag ctt 768 
Leu Ala Thr Gly Ile Lys Pro Asp Thr Glu Phe Leu Glu Asn Gln Leu 
245 250 255 
aaa act act aaa aat gga gca ata att gta aat gag tat ggc gaa act 816 
Lys Thr Thr Lys Asn Gly Ala Ile Ile Val Asn Glu Tyr Gly Glu Thr 
260 265 270 
age ata aaa aat att ttt tct gca gga gat tgt gca act att tat aat 864 
Ser Ile Lys Asn Ile Phe Ser Ala Gly Asp Cys Ala Thr Ile Tyr Asn 
275 280 285 
ata gta agt aaa aaa aat gaa tac ata ccc ttg gca aca aca gee aac 912 
Ile Val Ser Lys Lys Asn Glu Tyr Ile Pro Leu Ala Thr Thr Ala Asn 
290 295 300 
aaa ctt gga aga ata gtt ggt gaa aat tta get ggg aat cat aca gca 960 
Lys Leu Gly Arg Ile Val Gly Glu Asn Leu Ala Gly Asn His Thr Ala 
305 310 315 320 
ttt aaa ggc aca ttg ggc tea get tea att aaa ata eta tct tta gaa 1008 
Phe Lys Gly Thr Leu Gly Ser Ala Ser Ile Lys Ile Leu Ser Leu Glu 
325 330 335 
get gca aga aca gga ctt aca gaa aaa gat gca aaa aag etc caa ata 1056 
Ala Ala Arg Thr Gly Leu Thr Glu Lys Asp Ala Lys Lys Leu Gln Ile 
340 345 350 
aaa tat aaa acg att ttt gta aag gac aaa aat cat aca aat tat tat 1104 
Lys Tyr Lys Thr Ile Phe Val Lys Asp Lys Asn His Thr Asn Tyr Tyr 
355 360 365 
cca ggc caa gaa gat ctt tat att aaa tta att tat gag gaa aat ace 1152 
Pro Gly Gln Glu Asp Leu Tyr Ile Lys Leu Ile Tyr Glu Glu Asn Thr 
370 375 380 
aaa ata ate ctt ggg gca caa gca ata gga aaa aat gga gee gta ata 1200 
Lys Ile Ile Leu Gly Ala Gln Ala Ile Gly Lys Asn Gly Ala Val Ile 
385 390 395 400 
aga att cat get tta tea att gca ate tat tea aaa ctt aca aca aaa 1248 
Arg Ile His Ala Leu Ser Ile Ala Ile Tyr Ser Lys Leu Thr Thr Lys 
405 410 415 
gag eta ggg atg atg gat ttc tea tat tee cca ccc ttc tea aga act 1296 
Glu Leu Gly Met Met Asp Phe Ser Tyr Ser Pro Pro Phe Ser Arg Thr 
420 425 430 
tgg gat ata tta aat att get ggc aat get gee aaa tag 
Trp Asp Ile Leu Asn Ile Ala Gly Asn Ala Ala Lys 
435 440 
<210> SEQ ID NO 8 
<211> LENGTH: 444 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 
Met Met Lys Ile Ile Ile Ile Gly Gly Thr Ser Ala Gly Thr Ser Ala 
1 5 10 15 
Ala Ala Lys Ala Asn Arg Leu Asn Lys Lys Leu Asp Ile Thr Ile Tyr 
20 25 30 
Glu Lys Thr Asn Ile Val Ser Phe Gly Thr Cys Gly Leu Pro Tyr Phe 
35 40 45 
Val Gly Gly Phe Phe Asp Asn Pro Asn Thr Met Ile Ser Arg Thr Gln 
50 55 60 
1335 
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-continued 
Glu Glu Phe Glu Lys Thr Gly Ile Ser Val Lys Thr Asn His Glu Val 
65 70 75 80 
Ile Lys Val Asp Ala Lys Asn Asn Thr Ile Val Ile Lys Asn Gln Lys 
85 90 95 
Thr Gly Thr Ile Phe Asn Asn Thr Tyr Asp Gln Leu Met Ile Ala Thr 
100 105 110 
Gly Ala Lys Pro Ile Ile Pro Pro Ile Asn Asn Ile Asn Leu Glu Asn 
115 120 125 
Phe His Thr Leu Lys Asn Leu Glu Asp Gly Gln Lys Ile Lys Lys Leu 
130 135 140 
Met Asp Arg Glu Glu Ile Lys Asn Ile Val Ile Ile Gly Gly Gly Tyr 
145 150 155 160 
Ile Gly Ile Glu Met Val Glu Ala Ala Lys Asn Lys Arg Lys Asn Val 
165 170 175 
Arg Leu Ile Gln Leu Asp Lys His Ile Leu Ile Asp Ser Phe Asp Glu 
180 185 190 
Glu Ile Val Thr Ile Met Glu Glu Glu Leu Thr Lys Lys Gly Val Asn 
195 200 205 
Leu His Thr Asn Glu Phe Val Lys Ser Leu Ile Gly Glu Lys Lys Ala 
210 215 220 
Glu Gly Val Val Thr Asn Lys Asn Thr Tyr Gln Ala Asp Ala Val Ile 
225 230 235 240 
Leu Ala Thr Gly Ile Lys Pro Asp Thr Glu Phe Leu Glu Asn Gln Leu 
245 250 255 
Lys Thr Thr Lys Asn Gly Ala Ile Ile Val Asn Glu Tyr Gly Glu Thr 
260 265 270 
Ser Ile Lys Asn Ile Phe Ser Ala Gly Asp Cys Ala Thr Ile Tyr Asn 
275 280 285 
Ile Val Ser Lys Lys Asn Glu Tyr Ile Pro Leu Ala Thr Thr Ala Asn 
290 295 300 
Lys Leu Gly Arg Ile Val Gly Glu Asn Leu Ala Gly Asn His Thr Ala 
305 310 315 320 
Phe Lys Gly Thr Leu Gly Ser Ala Ser Ile Lys Ile Leu Ser Leu Glu 
325 330 335 
Ala Ala Arg Thr Gly Leu Thr Glu Lys Asp Ala Lys Lys Leu Gln Ile 
340 345 350 
Lys Tyr Lys Thr Ile Phe Val Lys Asp Lys Asn His Thr Asn Tyr Tyr 
355 360 365 
Pro Gly Gln Glu Asp Leu Tyr Ile Lys Leu Ile Tyr Glu Glu Asn Thr 
370 375 380 
Lys Ile Ile Leu Gly Ala Gln Ala Ile Gly Lys Asn Gly Ala Val Ile 
385 390 395 400 
Arg Ile His Ala Leu Ser Ile Ala Ile Tyr Ser Lys Leu Thr Thr Lys 
405 410 415 
Glu Leu Gly Met Met Asp Phe Ser Tyr Ser Pro Pro Phe Ser Arg Thr 
420 425 430 
Trp Asp Ile Leu Asn Ile Ala Gly Asn Ala Ala Lys 
435 440 
<210> SEQ ID NO 9 
<211> LENGTH: 1335 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
68 
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-continued 
<223> OTHER INFORMATION: Synthetic 
<220> FEATURE: 
<221> NAME/KEY: CDS 
<222> LOCATION: (1) .. (1335) 
<400> SEQUENCE: 
atg atg aaa ata ata att att ggg ggc aca tea gca gga act agt gee 48 
Met Met Lys Ile Ile Ile Ile Gly Gly Thr Ser Ala Gly Thr Ser Ala 
1 5 10 15 
gca get aaa gca aac cgc tta aac aaa aag eta gac att act ate tat 96 
Ala Ala Lys Ala Asn Arg Leu Asn Lys Lys Leu Asp Ile Thr Ile Tyr 
20 25 30 
gaa aaa aca aat att gta tct ttt gga ace tgc ggc ctg cct tac ttt 144 
Glu Lys Thr Asn Ile Val Ser Phe Gly Thr Cys Gly Leu Pro Tyr Phe 
35 40 45 
gtg ggg gga ttc ttt gac aac ccc aat aca atg ate tea aga aca caa 192 
Val Gly Gly Phe Phe Asp Asn Pro Asn Thr Met Ile Ser Arg Thr Gln 
50 55 60 
gaa gaa ttc gaa aaa act gga ate tct gtt aaa act aac cac gaa get 240 
Glu Glu Phe Glu Lys Thr Gly Ile Ser Val Lys Thr Asn His Glu Ala 
65 70 75 80 
ate aaa gta gat gca aaa aac aat aca att gta ata aaa aat caa aaa 288 
Ile Lys Val Asp Ala Lys Asn Asn Thr Ile Val Ile Lys Asn Gln Lys 
85 90 95 
aca gga ace att ttt aac aat act tac gat caa ctt atg ata gca act 336 
Thr Gly Thr Ile Phe Asn Asn Thr Tyr Asp Gln Leu Met Ile Ala Thr 
100 105 110 
ggt gca aaa cct att att cca cca ate aat aat ate aat eta gaa aat 384 
Gly Ala Lys Pro Ile Ile Pro Pro Ile Asn Asn Ile Asn Leu Glu Asn 
115 120 125 
ttt cat act ctg aaa aat tta gaa gac ggt caa aaa ata aaa aaa tta 432 
Phe His Thr Leu Lys Asn Leu Glu Asp Gly Gln Lys Ile Lys Lys Leu 
130 135 140 
atg gat aga gaa gag att aaa aat ata gcg ata att ggt ggt gga tac 480 
Met Asp Arg Glu Glu Ile Lys Asn Ile Ala Ile Ile Gly Gly Gly Tyr 
145 150 155 160 
att gga att gaa atg gta gaa gca gca aaa aat aaa aga aaa aat gta 528 
Ile Gly Ile Glu Met Val Glu Ala Ala Lys Asn Lys Arg Lys Asn Val 
165 170 175 
aga tta att caa eta gat aag cac ata etc ata gat tee ttt gac gaa 576 
Arg Leu Ile Gln Leu Asp Lys His Ile Leu Ile Asp Ser Phe Asp Glu 
180 185 190 
gaa ata gtc aca ata atg gaa gaa gaa eta aca aaa aag ggg gtt aat 624 
Glu Ile Val Thr Ile Met Glu Glu Glu Leu Thr Lys Lys Gly Val Asn 
195 200 205 
ctt cat aca aat gag ttt gta aaa agt tta ata gga gaa aaa aag gca 672 
Leu His Thr Asn Glu Phe Val Lys Ser Leu Ile Gly Glu Lys Lys Ala 
210 215 220 
gga gga gta gta aca aac aaa aat act tat caa get gac get gtt ata 720 
Gly Gly Val Val Thr Asn Lys Asn Thr Tyr Gln Ala Asp Ala Val Ile 
225 230 235 240 
ctt get ace gga ata aaa cct gac act gaa ttt tta gaa aac cag ctt 768 
Leu Ala Thr Gly Ile Lys Pro Asp Thr Glu Phe Leu Glu Asn Gln Leu 
245 250 255 
aaa act act aaa aat gga gca ata att gta aat gag tat ggc gaa act 816 
Lys Thr Thr Lys Asn Gly Ala Ile Ile Val Asn Glu Tyr Gly Glu Thr 
260 265 270 
age ata aaa aat att ttt tct gca gga gat tgt gca act att tat aat 864 
Ser Ile Lys Asn Ile Phe Ser Ala Gly Asp Cys Ala Thr Ile Tyr Asn 
275 280 285 
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71 
-continued 
ata gta agt aaa aaa aat gaa tac ata ccc ttg gca aca aca gee aac 912 
Ile Val Ser Lys Lys Asn Glu Tyr Ile Pro Leu Ala Thr Thr Ala Asn 
290 295 300 
aaa ctt gga aga ata gtt ggt gaa aat tta get ggg aat cat aca gca 960 
Lys Leu Gly Arg Ile Val Gly Glu Asn Leu Ala Gly Asn His Thr Ala 
305 310 315 320 
ttt aaa ggc aca ttg ggc tea get tea att aaa ata eta tct tta gaa 1008 
Phe Lys Gly Thr Leu Gly Ser Ala Ser Ile Lys Ile Leu Ser Leu Glu 
325 330 335 
get gca aga acg gga ctt aca gaa aaa gat gca aaa agg etc caa ata 1056 
Ala Ala Arg Thr Gly Leu Thr Glu Lys Asp Ala Lys Arg Leu Gln Ile 
340 345 350 
aaa tat aaa acg att ttt gta aag gac aaa aat cat aca aat tat tat 1104 
Lys Tyr Lys Thr Ile Phe Val Lys Asp Lys Asn His Thr Asn Tyr Tyr 
355 360 365 
cca ggc caa gaa gat ctt tat att aaa tta att tat gag gaa aat ace 1152 
Pro Gly Gln Glu Asp Leu Tyr Ile Lys Leu Ile Tyr Glu Glu Asn Thr 
370 375 380 
aaa ata ate ctt gga gca caa gca aca gga aaa aat gga gee gta atg 1200 
Lys Ile Ile Leu Gly Ala Gln Ala Thr Gly Lys Asn Gly Ala Val Met 
385 390 395 400 
aga att cat get tta tea att gca ate tat tea aaa ctt aca aca aaa 1248 
Arg Ile His Ala Leu Ser Ile Ala Ile Tyr Ser Lys Leu Thr Thr Lys 
405 410 415 
gag eta agg atg atg gat ttc tea tat tee cca ccc ttc tea aga act 1296 
Glu Leu Arg Met Met Asp Phe Ser Tyr Ser Pro Pro Phe Ser Arg Thr 
420 425 430 
tgg gat ata tta aat att get ggc aat get gee aaa tag 
Trp Asp Ile Leu Asn Ile Ala Gly Asn Ala Ala Lys 
435 440 
<210> SEQ ID NO 10 
<211> LENGTH: 444 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 10 
Met Met Lys Ile Ile Ile Ile Gly Gly Thr Ser Ala Gly Thr Ser Ala 
1 5 10 15 
Ala Ala Lys Ala Asn Arg Leu Asn Lys Lys Leu Asp Ile Thr Ile Tyr 
20 25 30 
Glu Lys Thr Asn Ile Val Ser Phe Gly Thr Cys Gly Leu Pro Tyr Phe 
35 40 45 
Val Gly Gly Phe Phe Asp Asn Pro Asn Thr Met Ile Ser Arg Thr Gln 
50 55 60 
Glu Glu Phe Glu Lys Thr Gly Ile Ser Val Lys Thr Asn His Glu Ala 
65 70 75 80 
Ile Lys Val Asp Ala Lys Asn Asn Thr Ile Val Ile Lys Asn Gln Lys 
85 90 95 
Thr Gly Thr Ile Phe Asn Asn Thr Tyr Asp Gln Leu Met Ile Ala Thr 
100 105 110 
Gly Ala Lys Pro Ile Ile Pro Pro Ile Asn Asn Ile Asn Leu Glu Asn 
115 120 125 
Phe His Thr Leu Lys Asn Leu Glu Asp Gly Gln Lys Ile Lys Lys Leu 
130 135 140 
Met Asp Arg Glu Glu Ile Lys Asn Ile Ala Ile Ile Gly Gly Gly Tyr 
145 150 155 160 
1335 
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Ile Gly Ile Glu Met Val Glu Ala Ala Lys Asn Lys Arg Lys Asn Val 
165 170 175 
Arg Leu Ile Gln Leu Asp Lys His Ile Leu Ile Asp Ser Phe Asp Glu 
180 185 190 
Glu Ile Val Thr Ile Met Glu Glu Glu Leu Thr Lys Lys Gly Val Asn 
195 200 205 
Leu His Thr Asn Glu Phe Val Lys Ser Leu Ile Gly Glu Lys Lys Ala 
210 215 220 
Gly Gly Val Val Thr Asn Lys Asn Thr Tyr Gln Ala Asp Ala Val Ile 
225 230 235 240 
Leu Ala Thr Gly Ile Lys Pro Asp Thr Glu Phe Leu Glu Asn Gln Leu 
245 250 255 
Lys Thr Thr Lys Asn Gly Ala Ile Ile Val Asn Glu Tyr Gly Glu Thr 
260 265 270 
Ser Ile Lys Asn Ile Phe Ser Ala Gly Asp Cys Ala Thr Ile Tyr Asn 
275 280 285 
Ile Val Ser Lys Lys Asn Glu Tyr Ile Pro Leu Ala Thr Thr Ala Asn 
290 295 300 
Lys Leu Gly Arg Ile Val Gly Glu Asn Leu Ala Gly Asn His Thr Ala 
305 310 315 320 
Phe Lys Gly Thr Leu Gly Ser Ala Ser Ile Lys Ile Leu Ser Leu Glu 
325 330 335 
Ala Ala Arg Thr Gly Leu Thr Glu Lys Asp Ala Lys Arg Leu Gln Ile 
340 345 350 
Lys Tyr Lys Thr Ile Phe Val Lys Asp Lys Asn His Thr Asn Tyr Tyr 
355 360 365 
Pro Gly Gln Glu Asp Leu Tyr Ile Lys Leu Ile Tyr Glu Glu Asn Thr 
370 375 380 
Lys Ile Ile Leu Gly Ala Gln Ala Thr Gly Lys Asn Gly Ala Val Met 
385 390 395 400 
Arg Ile His Ala Leu Ser Ile Ala Ile Tyr Ser Lys Leu Thr Thr Lys 
405 410 415 
Glu Leu Arg Met Met Asp Phe Ser Tyr Ser Pro Pro Phe Ser Arg Thr 
420 425 430 
Trp Asp Ile Leu Asn Ile Ala Gly Asn Ala Ala Lys 
435 440 
<210> SEQ ID NO 11 
<211> LENGTH: 1335 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<220> FEATURE: 
<221> NAME/KEY: CDS 
<222> LOCATION: (1) .. (1335) 
<400> SEQUENCE: 11 
atg atg aaa ata ata att att ggg ggc aca tea gca gga act agt gee 48 
Met Met Lys Ile Ile Ile Ile Gly Gly Thr Ser Ala Gly Thr Ser Ala 
1 5 10 15 
gca get aaa gca aac cgc tta aac aaa aag eta gac att act ate tat 96 
Ala Ala Lys Ala Asn Arg Leu Asn Lys Lys Leu Asp Ile Thr Ile Tyr 
20 25 30 
gaa aaa aca aat att gta tct ttt gga ace tgt ggc ctg cct tac ttt 144 
Glu Lys Thr Asn Ile Val Ser Phe Gly Thr Cys Gly Leu Pro Tyr Phe 
35 40 45 
74 
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-continued 
gtg ggg gga ttc ttt gac aac ccc aat aca atg ate tea aga aca caa 192 
Val Gly Gly Phe Phe Asp Asn Pro Asn Thr Met Ile Ser Arg Thr Gln 
50 55 60 
gaa gaa ttc gaa aaa act gga ate tct gtt aaa act aac cac gaa gtt 240 
Glu Glu Phe Glu Lys Thr Gly Ile Ser Val Lys Thr Asn His Glu Val 
65 70 75 80 
ate aaa gta gat gca aaa aac aat aca att gta ata aaa aat caa aaa 288 
Ile Lys Val Asp Ala Lys Asn Asn Thr Ile Val Ile Lys Asn Gln Lys 
85 90 95 
aca gga ace att ttt aac aat act tac gat caa ctt atg ata gca act 336 
Thr Gly Thr Ile Phe Asn Asn Thr Tyr Asp Gln Leu Met Ile Ala Thr 
100 105 110 
ggt gca aaa cct att att cca cca ate aat aat ate aat eta gaa aat 384 
Gly Ala Lys Pro Ile Ile Pro Pro Ile Asn Asn Ile Asn Leu Glu Asn 
115 120 125 
ttt cat act ctg aaa aat tta gaa gac ggt caa aaa ata aaa aaa tta 432 
Phe His Thr Leu Lys Asn Leu Glu Asp Gly Gln Lys Ile Lys Lys Leu 
130 135 140 
atg gat aga gaa gag att aaa aat ata gtg ata att ggt ggt gga tac 480 
Met Asp Arg Glu Glu Ile Lys Asn Ile Val Ile Ile Gly Gly Gly Tyr 
145 150 155 160 
att gga att gaa atg gta gaa gca gca aaa aat aaa aga aaa agt gta 528 
Ile Gly Ile Glu Met Val Glu Ala Ala Lys Asn Lys Arg Lys Ser Val 
165 170 175 
aga tta att caa eta gat aag cac ata etc ata gat tee ttt gac gaa 576 
Arg Leu Ile Gln Leu Asp Lys His Ile Leu Ile Asp Ser Phe Asp Glu 
180 185 190 
gaa ata gtc aca ata atg gaa gaa gaa eta aca aaa aag ggg gtt aat 624 
Glu Ile Val Thr Ile Met Glu Glu Glu Leu Thr Lys Lys Gly Val Asn 
195 200 205 
ctt cat aca aat gag ttt gta aaa agt tta ata gga gga aaa aag gca 672 
Leu His Thr Asn Glu Phe Val Lys Ser Leu Ile Gly Gly Lys Lys Ala 
210 215 220 
gaa gga gta gta aca aac aaa aat act tat caa get gac get gtt ata 720 
Glu Gly Val Val Thr Asn Lys Asn Thr Tyr Gln Ala Asp Ala Val Ile 
225 230 235 240 
ctt get ace gga ata aaa cct gac act gaa ttt tta gaa aac cag ctt 768 
Leu Ala Thr Gly Ile Lys Pro Asp Thr Glu Phe Leu Glu Asn Gln Leu 
245 250 255 
aaa act act aaa aat gga gca ata att gta aat gag tat ggc gaa act 816 
Lys Thr Thr Lys Asn Gly Ala Ile Ile Val Asn Glu Tyr Gly Glu Thr 
260 265 270 
age ata aaa aat att ttt tct gca gga gat tgt gca act att tat aat 864 
Ser Ile Lys Asn Ile Phe Ser Ala Gly Asp Cys Ala Thr Ile Tyr Asn 
275 280 285 
ata gta agt aaa aaa aat gaa tac ata ccc ttg gca aca aca gee aac 912 
Ile Val Ser Lys Lys Asn Glu Tyr Ile Pro Leu Ala Thr Thr Ala Asn 
290 295 300 
aaa ctt gga aga ata gtt ggt gaa aat tta get ggg aat cat aca gca 960 
Lys Leu Gly Arg Ile Val Gly Glu Asn Leu Ala Gly Asn His Thr Ala 
305 310 315 320 
ttt aaa ggc aca ttg ggc tea get tea att aaa ata eta tct tta gaa 1008 
Phe Lys Gly Thr Leu Gly Ser Ala Ser Ile Lys Ile Leu Ser Leu Glu 
325 330 335 
get gca aga aca gga ctt aca gaa aaa gat gca aaa aag etc caa ata 1056 
Ala Ala Arg Thr Gly Leu Thr Glu Lys Asp Ala Lys Lys Leu Gln Ile 
340 345 350 
aaa tat aaa acg att ttt gta aag gac aaa aat cat aca aat tat tat 1104 
Lys Tyr Lys Thr Ile Phe Val Lys Asp Lys Asn His Thr Asn Tyr Tyr 
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-continued 
355 360 365 
cca ggc caa gaa gat ctt tat att aaa tta att tat gag gaa aat ace 1152 
Pro Gly Gln Glu Asp Leu Tyr Ile Lys Leu Ile Tyr Glu Glu Asn Thr 
370 375 380 
aaa ata ate ctt ggg gca caa gca ata gga aaa aat gga gee gta ata 1200 
Lys Ile Ile Leu Gly Ala Gln Ala Ile Gly Lys Asn Gly Ala Val Ile 
385 390 395 400 
aga att cat get tta tea att gca ate tat tea aag ctt aca aca aaa 1248 
Arg Ile His Ala Leu Ser Ile Ala Ile Tyr Ser Lys Leu Thr Thr Lys 
405 410 415 
gag eta ggg atg atg gat ttc tea tat tee cca ccc ttc tea aga act 1296 
Glu Leu Gly Met Met Asp Phe Ser Tyr Ser Pro Pro Phe Ser Arg Thr 
420 425 430 
tgg gat ata tta aat att get ggc aat get gee aaa tag 
Trp Asp Ile Leu Asn Ile Ala Gly Asn Ala Ala Lys 
435 440 
<210> SEQ ID NO 12 
<211> LENGTH: 444 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 12 
Met Met Lys Ile Ile Ile Ile Gly Gly Thr Ser Ala Gly Thr Ser Ala 
1 5 10 15 
Ala Ala Lys Ala Asn Arg Leu Asn Lys Lys Leu Asp Ile Thr Ile Tyr 
20 25 30 
Glu Lys Thr Asn Ile Val Ser Phe Gly Thr Cys Gly Leu Pro Tyr Phe 
35 40 45 
Val Gly Gly Phe Phe Asp Asn Pro Asn Thr Met Ile Ser Arg Thr Gln 
50 55 60 
Glu Glu Phe Glu Lys Thr Gly Ile Ser Val Lys Thr Asn His Glu Val 
65 70 75 80 
Ile Lys Val Asp Ala Lys Asn Asn Thr Ile Val Ile Lys Asn Gln Lys 
85 90 95 
Thr Gly Thr Ile Phe Asn Asn Thr Tyr Asp Gln Leu Met Ile Ala Thr 
100 105 110 
Gly Ala Lys Pro Ile Ile Pro Pro Ile Asn Asn Ile Asn Leu Glu Asn 
115 120 125 
Phe His Thr Leu Lys Asn Leu Glu Asp Gly Gln Lys Ile Lys Lys Leu 
130 135 140 
Met Asp Arg Glu Glu Ile Lys Asn Ile Val Ile Ile Gly Gly Gly Tyr 
145 150 155 160 
Ile Gly Ile Glu Met Val Glu Ala Ala Lys Asn Lys Arg Lys Ser Val 
165 170 175 
Arg Leu Ile Gln Leu Asp Lys His Ile Leu Ile Asp Ser Phe Asp Glu 
180 185 190 
Glu Ile Val Thr Ile Met Glu Glu Glu Leu Thr Lys Lys Gly Val Asn 
195 200 205 
Leu His Thr Asn Glu Phe Val Lys Ser Leu Ile Gly Gly Lys Lys Ala 
210 215 220 
Glu Gly Val Val Thr Asn Lys Asn Thr Tyr Gln Ala Asp Ala Val Ile 
225 230 235 240 
Leu Ala Thr Gly Ile Lys Pro Asp Thr Glu Phe Leu Glu Asn Gln Leu 
245 250 255 
1335 
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-continued 
Lys Thr Thr Lys Asn Gly Ala Ile Ile Val Asn Glu Tyr Gly Glu Thr 
260 265 270 
Ser Ile Lys Asn Ile Phe Ser Ala Gly Asp Cys Ala Thr Ile Tyr Asn 
275 280 285 
Ile Val Ser Lys Lys Asn Glu Tyr Ile Pro Leu Ala Thr Thr Ala Asn 
290 295 300 
Lys Leu Gly Arg Ile Val Gly Glu Asn Leu Ala Gly Asn His Thr Ala 
305 310 315 320 
Phe Lys Gly Thr Leu Gly Ser Ala Ser Ile Lys Ile Leu Ser Leu Glu 
325 330 335 
Ala Ala Arg Thr Gly Leu Thr Glu Lys Asp Ala Lys Lys Leu Gln Ile 
340 345 350 
Lys Tyr Lys Thr Ile Phe Val Lys Asp Lys Asn His Thr Asn Tyr Tyr 
355 360 365 
Pro Gly Gln Glu Asp Leu Tyr Ile Lys Leu Ile Tyr Glu Glu Asn Thr 
370 375 380 
Lys Ile Ile Leu Gly Ala Gln Ala Ile Gly Lys Asn Gly Ala Val Ile 
385 390 395 400 
Arg Ile His Ala Leu Ser Ile Ala Ile Tyr Ser Lys Leu Thr Thr Lys 
405 410 415 
Glu Leu Gly Met Met Asp Phe Ser Tyr Ser Pro Pro Phe Ser Arg Thr 
420 425 430 
Trp Asp Ile Leu Asn Ile Ala Gly Asn Ala Ala Lys 
435 440 
<210> SEQ ID NO 13 
<211> LENGTH: 37 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 13 
gcgcgaattc atgaaagtta ttgtagtagg ttgtact 
<210> SEQ ID NO 14 
<211> LENGTH: 37 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 14 
gcgcaagctt ttatttatgt gctttgtcag cttgtgc 
<210> SEQ ID NO 15 
<211> LENGTH: 36 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 15 
gcgcggatcc atgatgaaaa taataattat tggggg 
<210> SEQ ID NO 16 
<211> LENGTH: 37 
<212> TYPE: DNA 
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<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 16 
gcgcaagctt ctatttggca gcattgccag caatatt 
<210> SEQ ID NO 17 
<211> LENGTH: 452 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 17 
-continued 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe Ala Val 
1 5 10 15 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Ala Tyr Glu 
20 25 30 
Met Asn Asp Asn Ile Ser Phe Leu Ser Ser Gly Ile Ala Leu Tyr Leu 
35 40 45 
Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr Ser Ser 
50 55 60 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg His Gln 
65 70 75 80 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
Ile Thr Asn Glu Glu Lys Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Glu Leu Leu Lys Gly Lys Val 
245 250 255 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
82 
37 
US 7,163,815 B2 
83 
-continued 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
340 345 350 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
Lys Ala His Lys 
450 
<210> SEQ ID NO 18 
<211> LENGTH: 452 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 18 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe Ala Val 
1 5 10 15 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Ala Tyr Glu 
20 25 30 
Met Asn Asp Asn Ile Ser Phe Leu Ser Met Gly Ile Ala Leu Tyr Leu 
35 40 45 
Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr Ser Ser 
50 55 60 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg His Gln 
65 70 75 80 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
Ile Thr Asn Glu Glu Lys Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
84 
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-continued 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Glu Leu Leu Lys Gly Lys Val 
245 250 255 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
340 345 350 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
Lys Ala His Lys 
450 
<210> SEQ ID NO 19 
<211> LENGTH: 452 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 19 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe Ala Val 
1 5 10 15 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Ala Tyr Glu 
20 25 30 
Met Asn Asp Asn Ile Ser Phe Leu Ser Ala Gly Ile Ala Leu Tyr Leu 
35 40 45 
Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr Ser Ser 
50 55 60 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg His Gln 
65 70 75 80 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
Ile Thr Asn Glu Glu Lys Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
86 
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Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Glu Leu Leu Lys Gly Lys Val 
245 250 255 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
340 345 350 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
Lys Ala His Lys 
450 
<210> SEQ ID NO 20 
<211> LENGTH: 452 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic 
<400> SEQUENCE: 20 
Met Lys Val Ile Val Val Gly Cys Thr His Ala Gly Thr Phe Ala Val 
1 5 10 15 
Lys Gln Thr Ile Ala Asp His Pro Asp Ala Asp Val Thr Ala Tyr Glu 
20 25 30 
Met Asn Asp Asn Ile Ser Phe Leu Ser Phe Gly Ile Ala Leu Tyr Leu 
35 40 45 
88 
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Gly Lys Glu Ile Lys Asn Asn Asp Pro Arg Gly Leu Phe Tyr Ser Ser 
50 55 60 
Pro Glu Glu Leu Ser Asn Leu Gly Ala Asn Val Gln Met Arg His Gln 
65 70 75 80 
Val Thr Asn Val Asp Pro Glu Thr Lys Thr Ile Lys Val Lys Asp Leu 
85 90 95 
Ile Thr Asn Glu Glu Lys Thr Glu Ala Tyr Asp Lys Leu Ile Met Thr 
100 105 110 
Thr Gly Ser Lys Pro Thr Val Pro Pro Ile Pro Gly Ile Asp Ser Ser 
115 120 125 
Arg Val Tyr Leu Cys Lys Asn Tyr Asn Asp Ala Lys Lys Leu Phe Glu 
130 135 140 
Glu Ala Pro Lys Ala Lys Thr Ile Thr Ile Ile Gly Ser Gly Tyr Ile 
145 150 155 160 
Gly Ala Glu Leu Ala Glu Ala Tyr Ser Asn Gln Asn Tyr Asn Val Asn 
165 170 175 
Leu Ile Asp Gly His Glu Arg Val Leu Tyr Lys Tyr Phe Asp Lys Glu 
180 185 190 
Phe Thr Asp Ile Leu Ala Lys Asp Tyr Glu Ala His Gly Val Asn Leu 
195 200 205 
Val Leu Gly Ser Lys Val Ala Ala Phe Glu Glu Val Asp Asp Glu Ile 
210 215 220 
Ile Thr Lys Thr Leu Asp Gly Lys Glu Ile Lys Ser Asp Ile Ala Ile 
225 230 235 240 
Leu Cys Ile Gly Phe Arg Pro Asn Thr Glu Leu Leu Lys Gly Lys Val 
245 250 255 
Ala Met Leu Asp Asn Gly Ala Ile Ile Thr Asp Glu Tyr Met His Ser 
260 265 270 
Ser Asn Arg Asp Ile Phe Ala Ala Gly Asp Ser Ala Ala Val His Tyr 
275 280 285 
Asn Pro Thr Asn Ser Asn Ala Tyr Ile Pro Leu Ala Thr Asn Ala Val 
290 295 300 
Arg Gln Gly Arg Leu Val Gly Leu Asn Leu Thr Glu Asp Lys Val Lys 
305 310 315 320 
Asp Met Gly Thr Gln Ser Ser Ser Gly Leu Lys Leu Tyr Gly Arg Thr 
325 330 335 
Tyr Val Ser Thr Gly Ile Asn Thr Ala Leu Ala Lys Ala Asn Asn Leu 
340 345 350 
Lys Val Ser Glu Val Ile Ile Ala Asp Asn Tyr Arg Pro Glu Phe Met 
355 360 365 
Leu Ser Thr Asp Glu Val Leu Met Ser Leu Val Tyr Asp Pro Lys Thr 
370 375 380 
Arg Val Ile Leu Gly Gly Ala Leu Ser Ser Met His Asp Val Ser Gln 
385 390 395 400 
Ser Ala Asn Val Leu Ser Val Cys Ile Gln Asn Lys Asn Thr Ile Asp 
405 410 415 
Asp Leu Ala Met Val Asp Met Leu Phe Gln Pro Gln Phe Asp Arg Pro 
420 425 430 
Phe Asn Tyr Leu Asn Ile Leu Gly Gln Ala Ala Gln Ala Gln Ala Asp 
435 440 445 
Lys Ala His Lys 
450 
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What is claimed is: 
1. An isolated bacterial oxidase, comprising an oxidase 
that regenerates NADP+, NAD+, or both; 
wherein the oxidase is isolated from Lactobacillus; and 
wherein the bacterial oxidase protein comprises the amino 
acid sequence of SEQ ID NO.: 4. 
2. The bacterial oxidase of claim 1, wherein the oxidase 
is isolated from Lactobacillus sanfranciscensis. 
92 
6. The bacterial oxidase of claim 1, wherein the bacterial 
oxidase binds essentially equally to NADP+ or NAD+. 
7. The bacterial oxidase of claim 1, wherein the bacterial 
oxidase has a normalized conversion value of more than 
about 27 .9% using a cofactor regenerating assay. 
8. The bacterial oxidase of claim 1, wherein the bacterial 
oxidase has a turnover ratio of more than about 8.7 using a 3. The bacterial oxidase of claim 1, wherein the oxidase 
is encoded by a nucleic acid sequence comprising SEQ ID 
NO: 3. 
10 cofactor regenerating assay. 
4. The bacterial oxidase of claim 1, wherein the bacterial 
oxidase is capable of forming a reaction product comprising 
one or more chiral compounds. 
5. The bacterial oxidase of claim 1, wherein essentially no 15 
H2 0 2 is produced by the bacterial oxidase in a reaction for 
regenerating NADP+, NAD+, or both. 
9. The bacterial oxidase of claim 1, wherein the oxidase 
has a Km value of less than about 6.7 µM, wherein the Km 
value is the Km value of the binding of the oxidase with 
NADP+ or NAD+. 
* * * * * 
